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IKKβ is a key kinase in the canonical NF-κB pathway. Transient activation of IKKβ 
is required for normal immune response while sustained activation has been implicated in 
cancer. To date, no IKKβ inhibitor has been approved for clinical use as a 
chemotherapeutic, likely due to unexpected toxicities associated with blocking the 
transient activation of IKKβ. We hypothesized that an IKKβ inhibitor that allows transient 
activation of IKKβ, but not sustained activation of IKKβ, could inhibit cancer growth without 
inducing toxicity.   
 As such, we identified a small molecule inhibitor, 13-197, that allows the transient 
activation of IKKβ but not the sustained activation of IKKβ. 13-197 inhibits cancer growth 
without inducing toxicity. Structure activity relationship studies (SAR) were conducted with 
13-197 analogs to determine substituents key for activity against IKKβ-mediated NF-κB 
activity and the anticancer effects of 13-197 were studied in pancreatic cancer cells. 13-
197 inhibited NF-κB pathway proteins and decreased the expression of anti-apoptotic 
proteins.  
 To further explore options for the development of non-toxic IKKβ inhibitors, 25-4 
was designed to feature the -methylene--butyrolactone targeting motif of the IKKβ and 
NF-κB inhibitor parthenolide. Parthenolide is active against IKKβ and NF-κB in cell-based 
studies but the drug has not been approved as an anticancer treatment despite its effects 
in cells and lack of toxicity in clinical trials. SAR studies with 25-4 identified structural 




the molecule’s activity towards IKKβ and NF-κB. Cell-based studies with 25-4 demonstrate 
the molecule’s anticancer activities, such as growth inhibition, inhibition of colony 
formation and induction of apoptosis. Furthermore, 25-4 synergized with the clinical 
chemotherapeutic cisplatin to inhibit the viability of cancer cells. Future studies will 
elucidate the mechanistic basis for non-toxic inhibition of IKKβ by 25-4 and will focus on 
improving the drug-like properties of the small molecule. 
 Overall, these studies demonstrate that IKKβ is a viable target for anticancer 
treatment and establish 13-197 and 25-4 as novel inhibitors of IKKβ with IC50s comparable 
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Chapter 1: Background and Significance 
Introduction to the NF-κB pathway 
Nuclear factor kappa B (NF-κB) is a transcription factor that plays a key role in 
innate and adaptive immune responses, inflammation, cell growth and apoptosis. This 
pathway is activated by a myriad of stimuli such as tumor necrosis factor alpha (TNF), 
interleukin 1 (IL-1), phorbol myristate acetate (PMA), ultraviolet radiation and stress to 
name a few.1 In unstimulated cells, dimers of NF-κB are sequestered in the cytoplasm by 
inhibitor of nuclear factor κB (IκB). In cells stimulated 
with the pro-inflammatory cytokine TNF (Figure 1), 
IκBs are phosphorylated by the inhibitor of κB kinase 
(IKK) complex, polyubiquitinated, and degraded by 
the 26S proteasome, allowing NF-κB dimers to enter 
the nucleus and regulate transcription.2 The NF-κB 
pathway controls the expression of hundreds of 
genes, including genes encoding cytokines and 
chemokines, immunoreceptors, acute phase 
proteins, cell adhesion molecules, regulators of 
apoptosis and many transcription factors, among 
others.  The chemokines and cytokines regulated by 
NF-κB include interferon gamma,3 many of the 
interleukins4-7 and TNF8 to name a few. 
Immunoreceptors include CD80, which is necessary 
for co-stimulation of T cells,9, 10 IgG and IgE heavy chains11-13 and the immunoglobulin light 
chain κ for which the transcription factor is named.14 The cell adhesion molecules 
regulated by NF-κB include fibronectin,15 ICAM-116 and P-selectin.17 Acute phase proteins 
 
Figure 1: TNF induces 
IKKβ-mediated NF-κB-
driven transcription. Here, 
NF-κB pathway activation is 
driven by the pro-
inflammatory cytokine TNF 
and leads to the transcription 




include LPS binding protein18 and complement factor C4, which activates the extrinsic 
pathway of complement activation.19 Apoptotic genes controlled by NF-κB include both 
pro-apoptotic and pro-survival proteins such as Bax,20 Bcl-xL,21 Bcl-222, Mcl-1,23 survivin,24 
and X-linked inhibitor of apoptosis (XIAP).25 Important transcription factors regulated by 
NF-κB include p53,26 c-myc,27 A20,28 c-fos,29 relb,30 c-rel,31 IκB,32 nfκB133 and 2.34 Many 
of these transcription factors actually regulate the activity of NF-κB itself and serve to 
negatively regulate the pathway’s activity. Though very abridged, the list of NF-κB-
regulated genes given above demonstrates the importance of the tight regulation of this 
transcription factor in physiological and diseased states. As so many key processes are 
controlled by this pathway, improper or chronic activation of the pathway results in many 
diseases, including inflammatory diseases, immunodeficiency, autoimmunity and 
cancer.35 
The NF-κB family of proteins 
The NF-κB family of proteins is comprised of five members including p65 (RelA), 
RelB, c-Rel and NF-κB1 (p105) and NF-κB2 (p100), which are proteolytically processed 
to p50 and p52, respectively. Each member of the family forms homo- or heterodimers 
and share a Rel homology domain (RHD) which facilitates dimerization and binding to κB 
DNA elements. In resting cells, p65, RelB and c-Rel are bound to the inhibitory IκBs, which 
associate with the DNA-binding domains of the NF-κB family members and yield them 
transcriptionally inactive. The pro-forms of p50 and p52, on the other hand, contain ankyrin 
repeats similar to those in the IκBs that serve as inhibitors of nuclear translocation. Unlike 
the other NF-κB family members, p50 and p52 lack transactivation domains and thus 
serve as repressors of transcription unless bound to p65 or RelB.36 The domain 
architecture of the prototypical NF-κB subunit p65 can be seen in Figure 2. Once free, NF-
κB dimers translocate to the nucleus where they may bind to promoter or enhancer regions 
containing the κB consensus sequence 5′ GGGRNWYYCC 3′ (where N represents any 
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base, R represents any purine, W represents an adenine or thymine and Y represents a 
pyrimidine). The κB site sequence, however, is quite degenerate and different NF-κB 
dimers show binding preferences for different sites leading to transcription of particular 
genes by specific dimers. The crystal structures of NF-κB dimers reveal that an Ig-like 
domain located in the N-terminus of NF-κB is responsible for the selectivity towards 
particular κB sites.37 Though 15 possible dimers have been shown to exist, the p50/p65 
dimer is the most common dimer and is present in nearly all cell types.38 
The IκB family of proteins 
The IκB family of proteins contains six members including IκB, IκBβ, IκBε, IκBγ, 
Bcl-3 (B-cell lymphoma 3) and IκBζ. IκB, IκBβ and IκBε are considered typical IκB 
proteins (along with the precursor proteins p105 and p100, which can be grouped as NF-
κB or IκB family members) and serve to retain NF-κB dimers in the cytoplasm. Degradation 
of the typical IκBs occurs once the protein has been phosphorylated on two serine 
residues within the consensus sequence (DS∗GXXS∗) by the kinase IKKβ. For IκB, 
which is the IκB that will be discussed in this dissertation, the phosphorylation occurs on 
residues 32 and 36. This phosphorylation event leads to recognition by βTrCP proteins 
 
Figure 2: Domain structure of the prototypical members of the NF-κB, IκB, and 
IKK families (top to bottom). The name of the protein is listed to the left and the 
number of amino acids in the protein is listed on the right. Domains discussed in this 
dissertation are listed. RHD, Rel homology domain; TA, transactivation; ANK, 
ankyrin; PEST, proline, glutamate, serine and threonine-enriched domain; KD, 
kinase domain; ULD, ubiquitin-like domain; SDD, scaffold and dimerization domain; 
NBD, NEMO-binding domain; CC, coil coil domain; LZ, leucine zipper; and Z, zinc 
finger. Adapted from references 41, 46 
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and K48-linked polyubiquitination by the Skp1-Culin-Roc1/Rbx1/Hrt-1-F-box family of E3 
ligases (SCFβTrCP-E3 ligase complexes) and the E2 UbcH5 and subsequent degradation 
in the 26S proteasome, which consequently allows NF-κB dimers to translocate to the 
nucleus.37 Dimers composed of p65 and p50 are primarily associated with IκB. Structural 
analysis of the complex composed of IκB, p65 and p50 revealed that IκB hides the 
nuclear localization sequence (NLS) of p65 but does nothing to mask the NLS of p50.39, 40 
As such, the balance between the NLS of p50 and the nuclear export sequence (NES) of 
IκB results in shuttling of the complex between the nucleus and cytosol, though 
localization of the complex appears to be cytosolic. IκB phosphorylation, ubiquitination 
and degradation, however, shifts the equilibrium of the complex towards the nucleus by 
eliminating the NES in IκB and exposing the NLS of p65.38 IκB is a better substrate for 
IKKβ than IκBβ or IκBε resulting in its rapid degradation.41, 42  
IκBβ and IκBε are degraded more slowly than IκB or not at all.41 Both IκBs are 
degraded and resynthesized upon stimulation of the NF-κB pathway but their kinetics differ 
from that of IκB and their roles in NF-κB signaling are still poorly understood. For example, 
deletion of IκBβ has no effect on the kinetics of NF-κB signaling but knocking IκBβ in to 
replace IκB also does not affect the kinetics of the pathway, suggesting that resynthesis 
of the two proteins plays a major role in the cellular effects.43, 44 
The atypical members of the IκB family include Bcl-3 and IκBζ and their roles are 
still not well understood. Bcl-3 features a transactivation domain and has been found in 
the nucleus in complex with p50 and p52 homo-dimers. In the case of p50, Bcl-3 may 
relieve transcriptional repression by removing p50 homodimers from κB elements. On the 
other hand, Bcl-3 may also stabilize p50 homodimers and prevent access of other TAD-
containing NF-κB dimers to κB elements. With p52, Bcl-3 may potentiate transcriptional 
activation, particularly of Cyclin D1. IκBζ is not constitutively expressed but is up-regulated 
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in response to IL-1 and TLR4 ligands, but not TNF41 and thus will not be discussed at 
length here. 
As more data regarding the function of the IκB family members becomes available, 
it is increasingly clear that these proteins can no longer be considered only inhibitors of 
NF-κB signaling. Nevertheless, the main IκB discussed in this dissertation will be IκB and 
its only important role for this work will be its binding to and prevention of translocation of 
p65/p50-containing heterodimers. 
The IKK complex and canonical (IKKβ-dependent) NF-κB signaling 
 The IKK complex is a 550-900 kDa complex composed of IKK (85 kDa), IKKβ (87 
kDa), and IKKγ, which is also referred to as NEMO (48 kDa).45 The complex was originally 
identified by immunoprecipitation and anion exchange chromatography of fractionated 
whole cell extracts from HeLa cells that had been stimulated with TNF. IKK and IKKβ 
were subsequently established as catalytic subunits while NEMO was determined to be a 
regulatory subunit. IKK and IKKβ share 51% sequence identities and are highly 
homologous in their kinase domains. A main structural difference between the two is the 
presence of an ubiquitin like domain (ULD) on IKKβ that is not predicted in IKK. 
Furthermore, IKK contains a nuclear localization sequence that is not present in IKKβ. 
NEMO, on the other hand, is structurally unrelated to IKK and IKKβ and is composed of 
two coil-coil domains, a leucine zipper, a zinc finger domain and a minimal oligomerization 
domain (MOD) that may allow NEMO to oligomerize.1 
Though it has not been conclusively proven and the discrepancy between the 
molecular weights of the core components of the IKK complex and the observed molecular 
weight of the purified complex has caused much debate over the years, it is currently 
believed that the active IKK complex is composed of a tetramer of NEMO subunits that 
brings an IKK/β heterodimer together.45 However, IKKβ activation of the NF-κB pathway 
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in cells lacking IKK is clear evidence that homodimers also interact with NEMO.1 IKK 
and IKKβ bind NEMO via a C-terminal NEMO binding domain (NBD). The regulation of 
the kinase activity associated with the IKK complex is not fully understood. NEMO-induced 
oligomerization is believed to induce a conformational change in IKK/β heterodimers. 
IKK/β heterodimers are then activated by upstream kinases such as TAK1 or trans-
autophosphorylation of T-loop serine residues (177 and 181 of IKKβ) for canonical 
pathway activation.45 Dimerization of IKK/β monomers is known to play a role in the 
activation or activity of the kinase. For example, dimerization mutations L654D/W655D 
and W655D/L658D exhibit complete or partial loss of activation in a manner that correlates 
with their degree of impairment in dimerization and failure to interact appropriately with 
NEMO. Additionally overexpression of IKKβ has been shown to result in activation. More 
recent studies suggest that IKKβ may exist as a dimer of dimers in cells and that 
neighboring dimers may be able to autophosphorylate one another to drive activation46 or 
an active kinase from a protomer in a neighboring dimer may activate an inactivate 
protomer in a separate dimer without forming a true tetramer.47 
In any event, it is widely accepted that the canonical NF-κB pathway is activated 
by inflammatory cytokines, such as TNF, pathogen-associated molecules or antigen 
receptors. For this pathway to function properly, IKKβ activation is both necessary and 
sufficient and leads to the phosphorylation of IκB in a NEMO-dependent manner. The 
non-canonical pathway is dependent on IKK and is activated by BAFF, lymphotoxin-B or 
CD40 ligand, the upstream kinase NIK (NF-κB-inducing kinase) and phosphorylation of 
p100.38 As this dissertation focuses on the activation of the NF-κB pathway by IKKβ in 
response to the pro-inflammatory cytokine TNF, the non-canonical pathway will not be 
discussed further.  
7 
 
Once activated by phosphorylation of its T-loop serine residues, IKKβ exhibits high 
activity and phosphorylates its substrate, IκB, and autophosphorylates several C-
terminal serine residues. The autophosphorylation results in decreased IKKβ kinase 
activity probably through another conformational change in the catalytic domain.48 The 
phosphorylated C-terminal serine residues provide binding sites for phosphatases such 
as PPM1A, PPM1B49 and PP2A50 that may dephosphorylate the T-loop serine residues. 
Another mode of regulation is through the phosphorylation of serine 740 in the NBD, which 
leads to the dissociation of the regulatory subunit NEMO. This also allows phosphatases 
to dephosphorylate the T-loop serine residues.2  
How else NEMO may regulate the activity of the IKK complex is under 
investigation. Mutation of the MOD of NEMO may hamper activation of NF-κB. 
Additionally, binding of NEMO to chains of polyubiquitin may also be key to activation of 
the IKK complex and many groups have demonstrated NEMO binding to upstream 
kinases with polyubiquitin chains, suggesting that NEMO may play a role in IKKβ activation 
by directing the IKK complex to upstream kinases. NEMO may also activate IKKβ in 
response to nuclear stimuli such as DNA damage. NEMO, free in the nucleus, may 
become SUMOylated and may then be exported to the cytoplasm where it can activate 
IKKβ and the NF-κB pathway. Furthermore, NEMO may also negatively regulate IKKβ 
activity through interaction with phosphatases (PP2A and PP2C) and deubiquitinases 
(CLYD and A20).1 
Signaling upstream of the IKK complex 
Signaling upstream of the IKK complex involves many adaptor proteins and likely 
an upstream kinase (Figure 3). Following binding of TNF, the cytoplasmic tail of TNFR1 
(TNF receptor 1) recruits a series of proximal adapter proteins through its death domain. 
TRADD (TNFR-associated protein with a death domain) and RIP1 (receptor-interacting 
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protein 1) bind to the death domain of TNFR1 through their own death domains though 
the mechanism is poorly understood. TRADD also recruits FADD (Fas-associated protein 
with death domain) again via their death domains and TRAF2/5 via a TRAF-binding 
domain in TRADD. TRAF2/5 in turn recruits cIAP1 and 2 (cellular inhibitor of apoptosis 1 
and 2), which facilitates the recruitment of the 
ubiquitin chains required for the activation of the 
IKK complex.45 TRAF2, along with the cIAPs, 
mediates linear or K63-linked ubiquitination of 
RIP1. RIP1 and TRAF2 thus cooperate to recruit 
tumor growth factor β activated kinase (TAK1), 
the upstream kinase likely responsible for 
phosphorylation and activation of IKKβ and the 
IKK complex.51 TAK1 is recruited to the adapter 
proteins associated with TNFR1 via the TAK 
binding proteins TAB2 and TAB3, which bind to 
the K63 polyubiquitin chains on TRAF2, RIP1 or 
NEMO. Furthermore, NEMO has been shown to 
bind K63 polyubiquitin chains on RIP1 
suggesting the ubiquitinated protein may bring 
the IKK complex and the upstream kinase TAK1 
together to promote IKKβ activation.41 
TNF 
 TNF is synthesized as a 26 kDa, 233 amino acid propeptide that is cleaved by 
TNF-converting enzyme into its 17 kDa, 157 amino acid form. TNF binds to TNFR1, 
which is expressed on nearly all mammalian cells, as a homotrimer, resulting in the 
 
Figure 3: Signaling upstream of 
the IKK complex. Signaling from 
TNFR1 through proximal adaptor 
proteins leads to activation of the 
IKK complex through IKKβ T loop 
phosphorylation (S177 and S181), 
which is indispensable for canonical 
NF-κB signaling. FADD, Fas-
associated protein with death 
domain; TRADD, TNFR-associated 
protein with a death domain; TRAF, 
TNFR-associated factor; cIAP, 
cellular inhibitor of apoptosis; ubiq., 
ubiquitin. Image adapted from ref38 
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dissociation of the silencer of death domain (SODD) protein that represses TNFR1 
signaling in the absence of TNF to activate the NF-κB pathway as previously described. 
Activated macrophages are the primary source of TNF, though the propeptide can be 
synthesized by other cells, including fibroblasts and tumor cells.52 
Inactivation of NF-κB pathway signaling 
 Unfortunately, the mechanisms that regulate the termination of NF-κB signaling 
are not yet well understood. It is known that IκB along with p105 and p100 are target 
genes of NF-κB and serve as regulatory molecules that influence NF-κB activity. Newly 
synthesized IκB, for example, can enter the nucleus and bind to NF-κB, causing it to 
shuttle back to the cytoplasm. Post-translational modification of NF-κB is also implicated 
in inactivation of pathway signaling. These post-translational modifications alter cofactor 
binding or can result in the displacement or degradation of NF-κB to terminate signaling.51 
Acetylation of p65, for example, results in decreased DNA-binding affinity.53 The ubiquitin 
ligases SOCS-1 and PDLIM2 have been shown to drive proteasomal degradation of p65 
bound to promoters.54-56 
Phosphorylation of tumor suppressor proteins: NF-κB-independent IKK functions 
Sequence analysis of IKKβ substrates using IκB peptides revealed a consensus 
sequence in the C-terminus of p53. Phosphorylation of p53 typically leads to protein 
stabilization by blocking Mdm2-mediated ubiquitination and degradation of the protein; 
however, other phosphorylation events have been shown to lead to p53 degradation. 
Studies with IKKβ and p53 showed that phosphorylation of p53 at S362 and S366 by IKKβ 
resulted in β-TrCP-mediated ubiquitination and degradation of the protein. Furthermore, 
activation of the NF-κB pathway by doxorubicin, which induces DNA damage, resulted in 
IKKβ-induced p53 phosphorylation and degradation.57  
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Tuberous sclerosis complex 1 and 2 are tumor suppressor proteins that form a 
complex that controls the activity of molecular target of rapamycin (mTOR). TSC1 binds 
to TSC2 and protects it from ubiquitination and degradation. TSC2 is a GTPase-activating 
protein that converts RHEB-GTP to RHEB-GDP and its activity prevents the activation of 
mTOR by RHEB-GTP. IKKβ has been shown to phosphorylate TSC1 at S487 and S511 
following activation by TNF. This phosphorylation event results in the destruction of the 
TSC complex and activation of mTOR, which provides a link between inflammation via the 
NF-κB pathway and tumorigenesis via activation of the mTOR pathway.58 
Phosphorylation of FOXO3a by IKKβ has also been found to lead to the protein’s 
ubiquitination and degradation in the absence of Akt. Activated Akt has been shown to 
phosphorylate FOXO3a, leading to the protein’s release from DNA and translocation to 
the cytoplasm where the protein binds 14-3-3 and becomes sequestered. In the absence 
of growth factor or survival stimuli, Akt is inactive and FOXO3a remains in the nucleus 
where it controls the transcription of genes involved in control of cell cycle progression 
and mitosis. However, in cells with inactive Akt, phosphorylation of FOXO3a by the IKK 
complex and subsequent degradation of the protein has been shown. Importantly, this 
regulation of FOXO3a by the IKK complex may contribute to tumor cell growth and 
tumorigenesis.59 
IKK knock-out models 
IKK knock-out mice survive until a month past birth but have abnormal skin, lack 
whiskers, and have limbs that do not form properly. These mice show reduced activation 
of the NF-κB pathway in response to inflammatory signals but the remaining IKK complex 
(composed of IKKβ homodimers and NEMO) is still capable of IκB phosphorylation and 
pathway activation in response to TNF.60 
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In mice, IKKβ deletion is embryonically lethal at day E13 due to massive apoptosis 
in the liver and IKKβ knock-out mouse embryonic fibroblasts (MEFs) exhibit increased 
apoptosis following treatment with TNF.61, 62 The knock-out mice can be rescued by 
crossing IKKβ-/- mice with TNFR-/- mice but the resulting pups still only survive until one 
month past birth. IKKβ knock-out MEFs still respond to certain stimuli associated with the 
canonical IKKβ-IκB-NF-κB pathway but deletion of NEMO results in a complete loss of 
this activity.1 
Mouse embryonic fibroblasts lacking NEMO are unable to respond to TNF. Like 
IKKβ-/- mice, mice lacking NEMO die during embryogenesis due to liver apoptosis and fail 
to respond to pro-inflammatory, immune and pro-survival stimuli.63 
IKK/β double knock-out mice die at E12 due to apoptosis and defective 
neuralation. TNF, IL-1 and LPS are all unable to activate the NF-κB pathway in double 
knock-out MEFs.64 Though crossing the double knock-out mice with TNF-/- mice does 
extend survival and yields mice more closely resembling IKK-/- mice, these mice still die 




Chapter 2: The NF-κB pathway and cancer 
TNF and the tumor microenvironment 
 In 1863, Rudolf Virchow posed a link between inflammation and cancer and over 
a century and a half later that link has been generally accepted.65 Furthermore, it is now 
postulated that up to 20% of cancers are due to underlying inflammatory responses such 
as infection, autoimmune disease or inflammation due to unknown causes. Many 
correlations between inflammation and cancer exist, including: 1) the fact that patients 
with inflammatory diseases are at increased risk for a diverse array of cancers including 
cervical and ovarian cancers, 2) the risk of developing cancers such as breast or colon 
cancer is decreased by the use of non-steroidal anti-inflammatory drugs, 3) inflammatory 
pathways often operate downstream of oncogenic mutations, 4) inhibition of inflammatory 
pathways, such as the NF-κB pathway, or inflammatory cells reduces the incidence of 
cancer and 5) activation of inflammatory pathways or transfer of inflammatory cells 
promotes tumor development. Two pathways of inflammation exist in cancer including the 
extrinsic pathway, which is a pathway activated by inflammatory conditions that increase 
the risk of cancer, and the intrinsic pathway, which is activated by genetic alternations that 
activate inflammation. At least one of these pathways is active in most, if not all, tumors.66 
This inflammation is caused by infiltrating immune cells, such as tumor-associated 
macrophages, that secrete pro-inflammatory cytokines, including TNF into the tumor 
microenvironment.67 
The importance of TNF and the NF-κB pathway has been clearly established in 
cancer. In resected tumor specimens, IKKβ is phosphorylated at S181 and thus activated 
in approximately 50% of tumor specimens, including breast, oral, stomach, colon, liver, 
and pancreatic tumor specimens. This phosphorylation is only seen in approximately 12% 
of normal tissues, suggesting that IKKβ and the NF-κB pathway are inappropriately 
13 
 
activated in cancer. Furthermore, in breast cancer tissues, there is a near perfect 
correlation between the phosphorylation of IKKβ S181 and the presence of TNF and the 
phosphorylation of IKKβ and the phosphorylation of IκB, suggesting that TNF in the 
tumor microenvironment drives the chronic activation of the NF-κB pathway (Figure 1).58 
Though REL deletions, mutations and amplifications have been seen in human cancers, 
this continuous activation of IKKβ and the NF-κB pathway by TNF in the tumor 
microenvironment likely plays a huge role in 
solid tumor formation.35 
Activation of the Ras-Raf signaling 
pathway results in the production of 
chemokines and cytokines that promote 
tumorigenesis via the intrinsic pathway. 
Importantly, K-Ras is mutated in many 
cancers, including those of the pancreas, 
colon, small intestine and lung. However, the 
extrinsic pathway likely also plays a role in 
cancers such as pancreatic cancer where 
both inflammation prior to a genetic lesion and 
subsequent mutations in K-Ras drive cancer 
progression. The intimate relationship 
between Ras activation and activation of IKK 
and the NF-κB pathway will be discussed in detail in the next section. 
The NF-κB pathway and solid tumors 
Activation of the NF-κB pathway is implicated in a number of solid tumors, including 
colon,58, 68-70 pancreatic,71-73 lung,74, 75 breast58, 76-79 and ovarian 80-82 cancers and has been 
 
Figure 1: Constitutive activation 
of the NF-κB pathway in cancer 
cells. TNF in the tumor 
microenvironment drives activation 
of IKK and subsequent 
phosphorylation and degradation of 
IκB and translocation of NF-κB to 




shown to play a role in inflammation, transformation, proliferation, angiogenesis, invasion, 
metastasis, chemoresistance and radioresistance.83 In this section, I will focus primarily 
on cancers that were used as model systems in this dissertation. 
Colon cancer 
Though no colon cancer cell lines were used in the body of work presented in this 
dissertation, the link between NF-κB activation and colon cancer is worth mentioning here. 
Deletion of IKKβ in enterocytes is associated with a decreased incidence of colitis-
associated tumor formation. In this model, mice were treated with dextran sulfate sodium 
salt to mimic inflammatory bowel disease after an initial treatment with the procarcinogen 
azoxymethan, which results in tumor formation in the distal colon. A 75% decrease in 
tumor incidence was noted in the IKKβ knock-out mice compared to wild-type controls. 
This decrease was due to increased apoptosis in knock-out mice. Furthermore, deletion 
of IKKβ in myeloid cells decreased tumor incidence in the same model by 50% but this 
was not related to apoptosis and was likely due to blocking the transcription of one or more 
NF-κB-dependent genes.68 Additionally, phosphorylated IKKβ was detected in over 65% 
of all colon cancer specimens analyzed by Mein Chi Hung’s group, suggesting there is a 
connection between pro-inflammatory TNF in the tumor microenvironment and colon 
cancer.58 Other groups have shown that NF-κB activation correlates with tumor 
progression69 and inhibition of NF-κB with a superrepressor IκB (a nonphosphorylable 
IκB with serine residues 32 and 36 converted to alanine residues) sensitizes colorectal 
cancer cells to treatment with the chemotherapeutic CPT-11.70 
Pancreatic cancer 
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the US, 
with a 5-year survival rate hovering around 5%.84 Three types of precancerous lesions 
may form prior to the onset of pancreatic ductal adenocarcinoma. These lesions include 
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intraductal papillary mucinous neoplasms (IPMNs), which form in the main pancreatic duct 
or its branches, pancreatic intraepithelial neoplasias (PanINs), which form within 
intralobular ducts and mucinous cystic neoplasms (MCN), which are epithelial neoplasms 
that produce mucin. Each of these precancerous lesions are believed to represent the 
progression from normal pancreatic cells to pancreatic ductal adenocarcinoma.85, 86 The 
connection between mutant K-Ras and IKK activation has been well established in the 
development of pancreatic cancer. 
K-Ras is mutated in approximately 90% of pancreatic ductal adenocarcinomas and 
this mutation can be seen in as many as 40% of PanIN lesions, suggesting the mutation 
is a very early event.87, 88 Furthermore, nearly half of ductal lesions displaying no atypia 
harbor the mutation and increased prevalence of this mutation is seen with increasing 
atypia.85 In mice, K-Ras mutation appears to be a primary event that results in the 
formation of premalignant ductal lesions that resemble human PanINs, but a second 
mutation is required for malignant progression.89 NF-κB is constitutively activated in 
approximately 67% of pancreatic adenocarcinomas90 and targeted inactivation of IKKβ in 
KrasG12D mice has been shown to stall pre-malignant PanIN lesions from developing into 
pancreatic ductal adenocarcinoma (PDAC).72, 73 The necessity of this constitutive 
activation of NF-κB for development of PDAC was made clear by work showing that 
pancreas-targeted IKKβ inactivation inhibited NF-κB activation and PDAC development in 
KrasG12D and KrasG12D;Ink4a/ArfF/F mice.91 These mice develop PanIN lesions but do 
not progress to PDAC when IKKβ is inactivated, supporting the importance of IKKβ 
activation in pancreatic cancer and suggesting that inhibition of the kinase may serve to 
prevent the development of the disease.72 
The importance of IKK activation in K-RasG12V–driven pancreatic cancer has also 
been established. Knocking K-RasG12V into the pancreatic acinar cells of mice results in 
the development of PanINs and PDAC that perfectly resembles human disease.92 
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However, if K-RasG12V is turned on in adult mice, the mice fail to develop PanINs and 
PDAC in the absence of chronic pancreatitis, the onset of which induces PanINs and 
PDAC. This work clearly demonstrates the necessity of inflammation for the formation of 
K-Ras-driven PDAC.93 
Lung cancer 
Lung cancer is another devastating disease with a 5-year survival rate of 
approximately 15%. To demonstrate the importance of IKKβ activation downstream of 
oncogenic mutation in a mouse model of non-small cell lung cancer, the researchers in 
Inder Verma’s group crossed IKKβfl/fl mice with KrasG12D mice to activate KrasG12D to initiate 
tumor formation but inactivate IKKβ upon transduction by Cre lentiviral vectors. The 
resulting KrasG12D/IKKβfl/fl mice survived longer (162 days median survival time compared 
to 114 days) than KrasG12D mice when each were infected with an appropriate lentiviral 
vector also encoding shRNA against p53 to speed tumor formation. Subsequent studies 
determined that these results were due to a pro-proliferation contribution of the NF-κB 
pathway in that particular model.94 Overexpression of IκB in lung cancer models has 
been associated with increased sensitivity to paclitaxel, possibly through reduced VEGF 
expression.75 
Breast cancer 
There is a near perfect correlation between the presence of TNF, activation of 
IKKβ and phosphorylation of IκB in over one-third of breast cancer tissues. This 
activation of IKKβ has been associated with phosphorylation of TSC1, which leads to 
dissociation of the protein from TSC2 and the subsequent degradation of TSC2 and 
activation of mTOR to drive VEGF production. Furthermore, this phosphorylation of TSC1 
correlates with decreased survival of patients from whom the tissues were collected.58 
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Estrogen receptor is expressed in approximately 70% of breast cancers and 
mediates the activation of estrogen, which is a key player in the initiation and progression 
of the disease. As the disease progresses, cancer cells lose their dependency for estrogen 
and become estrogen receptor negative (ER-) and this loss of ER has been shown to 
correlate with activation of the NF-κB pathway. Furthermore, ER is commonly used as a 
predictor of response to endocrine therapy, such as tamoxifen, for the treatment of breast 
cancer.76 DNA binding of NF-κB as measured by EMSA was much higher in ER- cell lines 
such as MDA-MB-231 cells than in ER+ cells lines and when an ER+ cell line was 
converted to an ER- cell line, NF-κB DNA binding activity doubled.77 Furthermore, the non-
steroidal anti-inflammatory agent sulindac has been shown to drive apoptosis in breast 
cancer cells through inhibition of IKKβ. Importantly, MDA-MB-231 cells, which show high 
activation of the kinase, were more sensitive to the drug than breast cancer cells with low 
IKKβ activation.78 Additionally, transient transfection of an endocrine-resistant MCF-7 cell 
line that has an approximately 50% higher level of NF-κB activity due to constitutive 
activation of Akt with the nonphosphoryable IκB (S32A/S36A) restores NF-κB activity to 
levels similar in control cells. Furthermore, tamoxifen treatment of cells transfected with 
the nonphosphorylable IκB resulted in increased growth inhibition of the endocrine-
resistance cells compared to tamoxifen treatment alone. Additionally, treatment with the 
IKKβ inhibitor parthenolide also enhanced tamoxifen-induced growth inhibition of the 
resistant cells.95 
Though NF-κB activation is more commonly associated with ER- breast cancers, 
NF-κB activity has also been shown in a subset of ER+ breast cancers and is associated 
with lower disease free survival. In these ER+ tumors, activation of NF-κB is shown to be 
higher in tumors with lower ER (21-87 fmol/mg ER vs. ≥100 fmol/mg ER). 76 
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The upregulation of NF-κB-related genes has also been implicated in inflammatory 
breast cancer, which is a rare and aggressive form of breast cancer. These genes include 
NF-κB genes such as NFKB1, RELA, NFKB2 and NEMO, tumor-promoting genes and 
genes that regulate angiogenesis, proliferation, apoptosis and immune responses.96 
Ovarian cancer 
IKKβ has been identified as a major promoter of a TLR4-MyD88-NF-κB pathway 
in epithelial ovarian cancer cells isolated from malignant ovarian cancer ascites and solid 
tumors. MyD88 is an adapter protein for TLR4 and expression of the protein allows 
signaling from TLR4 to NF-κB in MyD88+ epithelial ovarian cancer cells in response to 
LPS. Pathway activation by LPS induced increased growth and cytokine production in 
MyD88+ cells. Importantly, MyD88+ cells showed decreased sensitivity to the 
chemotherapeutic paclitaxel compared to MyD88- cells. In patients treated with paclitaxel 
and carboplatin following surgery, expression of MyD88 was correlated with decreased 
time until recurrence (23 months compared to 42 months for patients not expressing 
MyD88). Overall, these studies suggest that activation of the TLR4-MyD88-NF-κB 
pathway allows the epithelial ovarian cancer cells to constitutively secrete pro-
inflammatory cytokines to promote tumor progression and chemoresistance.80 
Subsequent work by the same group showed that treatment with LPS or paclitaxel results 
in increased NF-κB activity in MyD88+ cells but not MyD88- cells and that ectopic 
expression of IKKβ in MyD88- cells could induce production of the same cytokines 
produced by MyD88+ cells and restored TLR4 signaling. Furthermore, MyD88+ cells were 
shown to be resistant to apoptosis following treatment with high levels of TNF while 
MyD88- cells were sensitive to the treatment. Analysis of miRNAs in MyD88+ and MyD88- 
cells identified hsa-miR-199a as being up-regulated in MyD88- cells compared to MyD88+ 
cells and a regulator of IKKβ in MyD88- cells, establishing a role for the IKKβ and the NF-
κB pathway in ovarian cancer.81 A particularly important implication for this work is the role 
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it identifies for IKKβ and NF-κB in the development of resistance to paclitaxel. Though 
nearly 90% of ovarian cancer patients respond to treatments such as carboplatin and 
paclitaxel, most (again nearly 90%) will face recurrent disease.97 Pharmacological 
inhibition of the NF-κB pathway has been shown to increase ovarian cancer cell sensitivity 
to paclitaxel.82, 98 Furthermore, analysis of 42 primary tumors derived from patients with 
follow-up data showed that patients with tumors expressing IKKβ in at least 25% of cells 
had reduced overall survival (21 months compared to 29 months) compared to patients 
with IKKβ expression in 25% or fewer of their tumor cells. Furthermore, pharmacological 
inhibition or RNA interference of IKKβ resulted in decreased ovarian cancer cell viability.99 
Cervical cancer 
The role of NF-κB activation in cervical cancer is less clear than its role in 
previously discussed cancers. Infection with human papillomavirus (HPV) from the high 
risk subset of HPV is a major risk factor for the development of cervical cancer. The E6 
and E7 genes carried by HPV-16, a prototypical high-risk HPV strain, are required to 
immortalize human epithelial cells.100 E6 expression results in p53 degradation101 and 
immortalization through activation of hTERT102 while the E7 protein functions to inactivate 
retinoblastoma and thereby promotes progression of the cell cycle.103 These proteins also 
regulate NF-κB and NF-κB activation has been shown to decrease following 
immortalization of the epithelial cells more frequently giving rise to cervical cancer.104 The 
mechanism by which HPV inactivates NF-κB signaling appears to be through inhibition of 
the IKK complex.105 In the context of HPV infection and HPV-immortalization of cells, it 
appears that NF-κB actually plays a role in controlling the proliferation of virally infected 
cells and inhibition of NF-κB using the IκB superrepessor resulted in increased 
proliferation and colony formation of immortalized cells. Subsequent studies revealed that 
p65 functions to decrease expression of a short sequence of DNA upstream of HPV-16 
E6 and thereby inhibits proliferation.106 
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However, as cervical cancer progresses, the role of NF-κB seems to shift from 
inhibitory to activating.  For example, NF-κB overexpression has been shown to increase 
HeLa and C33A cell viability while knockdown of NF-κB suppresses cell viability. 
Furthermore, overexpression of NF-κB results in increased colony formation by both cell 
lines, indicating that NF-κB promotes cervical cancer cell viability and growth. In these 
studies it was found that NF-κB overexpression also increased miR-130a levels while 
knockdown of the protein decreased miR-130a levels. Expression of this microRNA is key 
for regulating TNF mRNA levels and the NF-κB/miR-130a/TNF feedback loop may be 
responsible for maintaining a level of TNF that promotes tumor growth and prevents 
apoptosis of cancer cells.107 
This seemingly two-faced role of NF-κB during the progression of cervical cancer 
is supported by immunohistochemical analysis of human tissues. In a series of 106 
cervical intraepithelial neoplasia (CIN lesions) and cervical cancer lesions analyzed, the 
NF-κB pathway was activated during the course of disease progression. In the normal 
cervix and early lesions (CIN1 lesions), p65 was localized exclusively to the cytoplasm but 
increased nuclear localization of p65 was seen during the progression of disease through 
CIN2 and CIN3 stages and the development of squamous-cell carcinoma of the cervix. As 
NF-κB serves to repress HPV transcription,108 the downregulation of NF-κB is likely 
required for initial infection and immortalization of cells but becomes less important during 
progression of the disease. Furthermore, NF-κB’s role in a myriad of tumor-promoting 
activities may select for its increased expression in precancerous lesions as the disease 
progresses, though the nuclear expression of NF-κB did not correlate with survival of 
patients, aggressiveness of disease or clearance or persistence of HPV infection.109 
Nevertheless, inhibition of the NF-κB pathway with curcumin and aspirin has been shown 
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to sensitize cervical cancer cells to chemotherapeutic agents such as cisplatin,110 which 
is consistent with the pathway’s role in the development of chemoresistance. 
Overall, the studies presented in this chapter establish TNF, IKKβ and NF-κB as 
key mediators of tumorigenesis and demonstrate the pathway’s importance in the 
progression of many solid tumors types. The next chapter will focus on the considerable 
efforts that have been made to develop IKKβ inhibitors and the challenges associated with 




Chapter 3: Targeting IKKβ 
Rationale for targeting IKKβ 
Nearly one-third of all cancers display an oncogenic mutation in Ras111 and IKKβ 
has been shown to be activated in 50% of tumors58 and its activation may serve as a 
second hit that results in the development of cancer.68, 72, 94 The case for pancreatic cancer, 
for example, is quite compelling. As mentioned previously, as many as 95% of human 
pancreatic carcinomas have been shown to harbor a mutation in codon 12 of the KRAS 
gene87 and NF-κB is constitutively activated in approximately 67% of pancreatic 
adenocarinomas90 and correlates with lower overall survival of patients.112 Constitutive 
activation of NF-κB has great implications for cancer research as it may lead to the 
transcription of anti-apoptotic genes, among others, and chemoresistance.113 Importantly, 
knock-out of IKKβ stalls Kras-driven pancreatic cancer at PanIN lesions, demonstrating a 
mechanistic link between mutated Kras and IKKβ in the initiation of PDAC, suggesting 
IKKβ is an attractive target for anticancer therapy.72 Furthermore, research suggests that 
inhibition of IKKβ may increase the efficacy of many chemotherapeutics such as 
gemcitabine,114, 115 paclitaxel82, 98 and cisplatin.110 
Current IKKβ inhibitors 
By the mid-2000’s research uncovering the undeniable role of the NF-κB pathway 
in inflammation and cancer had launched the development of many novel IKKβ inhibitors 
and the identification of natural products that blocked the kinase’s actions. The best-
studied of these inhibitors include BAY 11-7085,116 ML120B,117 TPCA-1,118 BMS345541119 
and Bayer ‘compound A’120 and the natural products curcumin121 and parthenolide.122 
Despite promising results in pre-clinical models, none of these drugs have been clinically 
approved for the treatment of cancer, due to unexpected toxicities arising from targeting 
IKKβ or poor bioavailability. For example, pre-treatment of HeLa cells with ML120B for 1 
hour followed by stimulation with TNF (30 ng/mL) for 5 minutes to drive activation of IKKβ 
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and phosphorylation of IκB, results in marked reduction in IκB phosphorylation. 
Unfortunately, when mice were dosed with ML120B for 7 days, a decrease in peripheral 
blood T cell and B cell numbers and an increase in granulocyte neutrophils was observed 
and mice had to be removed from the treatment due to toxicity issues.117, 123 These 
toxicities likely arise from inhibiting signaling through IKKβ required for proper immune 
functioning. The natural product parthenolide, on the other hand, did not display notable 
toxicity in a Phase I trial but instead suffered from the fact that a botanical product 
containing the natural product was not able to produce detectable levels of parthenolide 
in plasma.124 Taken together, these data suggest IKKβ represents a potential anticancer 
target, but its global inhibition is detrimental and careful design will be required to develop 
an IKKβ inhibitor that is viable for human use.   
Recent crystal structures of IKKβ 
 Recent crystal structures of IKKβ have provided structural insight that is quite 
valuable for the rational design of IKKβ inhibitors. One, published in 2011, was of Xenopus 
laevis IKKβ and yielded a proper understanding of the domain architecture of IKKβ.46 In 
this structure, the kinase domain of IKKβ is at the N-terminus of the protein and an 
ubiquitin-like domain follows. A scaffold/dimerization domain that contains previously 
predicted leucine zipper (LZ) and helix-loop-helix (HLH) domains is then followed by the 
C-terminal NEMO binding domain (Figure 1A). Previous models for the activation and 
subsequent deactivation of IKKβ depended on interactions facilitated by the predicted, but 
non-existent, LZ and HLH domains.125 Furthermore, hydrophobic residues of the predicted 
LZ domain actually point inward in the crystal structure and, therefore, are unavailable for 
mediating dimerization as the previous models proposed. Additionally, the previously 
discussed MEK consensus sequence motif of SxxxS (S represents S177 and S181 for 
IKKβ) was found in the activation loop of IKKβ. The crystal structure of Xenopus laevis 
IKKβ (which is commonly referred to as xIKKβ) was obtained using an IKKβ of residues 
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4–675 with S177 and S181 mutated to glutamic acid in complex with inhibitor.  The crystal 
 
 
Figure 1: Crystal structure of Xenopus laevis IKKβ. A) Domain architecture of IKKβ 
showing the KD, ULD, SDD and NBD of IKKβ B) Crystal structure of Xenopus laevis 
IKKβ with the KD, ULD, SDD and N- and C-termini of the kinase labeled C) Tetramer 
(dimer of dimers) formed by xIKKβ D) Close-up view of the activation loops of 
neighboring protomers. This research was originally published by Nature Publishing 
Group. Xu, G. et al. Crystal structure of inhibitor of kappaB kinase beta.  2011. Nature. 




structure captures IKKβ in a dimer resembling a pair of scissors with each kinase domain 
and ubiquitin-like domain representing handles and the scaffold/dimerization domain 
representing the blades of the shears, though the domains still intimately associate with 
one another (Figure 1B). The kinase domain exhibits a bilobal kinase fold, which is typical 
of all kinases, and the ubiquitin-like domain indeed has an ubiquitin fold and the 
hydrophobic surface patch of ubiquitin that is recognized by ubiquitin-binding proteins. The 
inhibitor binds to the hinge loop that connects the N- and C-lobes of the kinase domain of 
IKKβ, which is the same site where the adenine of ATP would bind and is the site targeted 
by most IKKβ inhibitors. Not surprisingly, the kinase domain is in a conformation that is 
not compatible with that of an active kinase. For example, the C-terminal anchor of the 
activation segment is in a conformation that results in loss of essential interactions with 
the catalytic center. Pulldowns with the C-terminal region of IκB and full-length IKKβ or 
the ULD-SDD region of IKKβ showed that the ankyrin repeats and PEST region of IκB 
interact with ULD-SDD IKKβ. Further studies demonstrated that the interaction directs the 
specificity of IKKβ to S32 and S36 of IκBa and away from its PEST sequence. Additionally, 
the interaction between the ubiquitin-like domain and the KD was found to allosterically 
position the KD in a confirmation that is favorable for catalysis. Lastly, the SDD domain 
was found to mediate dimerization between the two IKKβ monomers in the dimer. The 
interactions key for dimerization were mainly hydrophobic interactions between residues 
localized towards the end of the bundle. The tetrameric nature of the IKKβ crystal structure 
derived in these studies suggests that IKKβ may form a dimer of dimers that allows one 




A more recent crystal structure of human IKKβ residues 1-664 in complex with the 
staurosporine analog K252a captured an asymmetric dimer of IKKβ in which one IKKβ 
was phosphorylated at S177 and S181 while the other IKKβ protomer was not, yielding 
insight into the structural changes IKKβ undergoes when activated.47 The most significant 
differences between phosphorylated and nonphosphorylated IKKβ occurred in the N-
terminal lobe and at the activation loop (Figure 2A). Furthermore, the SDD of the 
unphosphorylated protomer (which is in gray) is rotated 6° away from the KD compared 
to the orientation of the SDD of the phosphorylated protomer and its KD (Figure 2B).47  
 
Figure 2: Crystal structure of an asymmetric dimer of human IKKβ. A) Ribbon 
diagram of the asymmetric human IKKβ dimer and B) overlay of the 
unphosphorylated and phosphorylated human IKKβ protomers. C) Overlay of the 
KDs of unphosphorylated and phosphorylated human IKKβ bound to inhibitor. D) 
Comparison of the pSer interactions of pS181 of human IKKβ and activated PKA. 
The PKA activation loop is shown in gray while that of IKKβ in shown in red. A bound 
peptide substrate is shown in blue. This research was originally published in J. Biol. 
Chem. Liu, S. et al. Crystal structure of a human IkappaB kinase beta asymmetric 
dimer. J. Biol. Chem. 2013; 288: 22758-67.47 
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The activation loop of the phosphorylated IKKβ (residues 166–194) assumes a 
conformation characteristic of an active kinase, as expected. The corresponding region of 
the unphosphorylated IKKβ is not well defined and is in a conformation that is not 
compatible with protein substrate binding (Figure 2C). As K252a binding is identical in 
both the phosphorylated and nonphosphorylated IKKβ protomers and packing of the two 
IKKβ protomers was equal, the differences in the flexibility and conformation of the two 
protomers is likely due to the differential phosphorylation. The three phosphate oxygens 
of pS181 interacted directly through ionic interactions with the cationic cluster formed by 
R144 from the catalytic loop and K171 from the activation loop. Furthermore, one of the 
phosphate oxygens formed hydrogen bonds to the main chain amide nitrogens of pS181 
and T180 (Figure 2C). These interactions likely provide a link to the catalytic center and 
stabilize the correct orientation of the catalytic base D145 and allow for the formation of 
the polypeptide substrate pocket. This is similar to what is seen with other kinases, such 
as Protein Kinase A (PKA) (Figure 2D).47  
These distinct conformations of the active and inactive IKKβ protomers reveals a 
well-formed peptide-binding pocket in active, but not inactive IKKβ (Figure 3A and B). 
Differences in the conformations of these crystal structures may allow targeting of active 
but not inactive IKKβ.47 
Unlike xIKKβ, the human IKKβ dimer adopted an open conformation with its KDs 
well separated, which is in contrast to the closed conformation adopted by xIKKβ (Figure 
4A and B). Furthermore, human IKKβ did not form a dimer of dimers but rather formed 
contacts with a crystal symmetry-related dimer at the KD and the N-terminal ends of the 
SDD to form a face-to-face KD-KD dimer. The activation loop (shown in red) in the 
nonphosphorylated human IKKβ molecule is close to the active site of the activated KD 
(Figure 5B), which is in contrast to what is seen with the dimer of dimers of xIKKβ (Figure 
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5A). This orientation may facilitate the trans-phosphorylation of an unactivated KD by an 
active kinase domain.47  
Historic IKKβ Inhibitors 
Historically, IKKβ inhibitors developed by pharmaceutical companies target the 
ATP binding site and thus the resting state of IKKβ. This mode of inhibition prevents the 
activation of IKKβ and likely results in the previously described toxicities. The crystal 
structure of the asymmetric IKKβ dimer sheds light on the possibility that the active, post-
translationally modified form of IKKβ represents a unique form of the kinase that can be 
targeted. This is particularly valuable information when coupled with the finding that IKKβ 
is chronically activated by TNF in the tumor microenvironment,58 which should result in 
a pool of phosphorylated IKKβ in cancerous cells (Figure 6). We hypothesized that small 
molecules targeting the phosphorylated form of IKKβ that accumulates in cancer but not 
the resting, unphosphorylated form of IKKβ that is found in normal tissues could serve as 
non-toxic inhibitors of IKKβ and the NF-κB pathway. As such, my dissertation work has 
focused on characterizing two small molecule inhibitors of IKKβ that we believe may target 
the activated form of the kinase to inhibit tumor growth without inducing toxicities. 
 
Figure 3: Comparison of the substrate binding sites in unphosphorylated and 
phosphorylated human IKKβ. The substrate binding site is not formed in the 
unphosphorylated protomer (A) but is well-formed in the phosphorylated protomer 
(B), allowing the binding of a peptide substrate. K252a is shown as a stick model and 
the substrate peptide is shown in blue. This research was originally published in J. 
Biol. Chem. Liu, S. et al. Crystal structure of a human IkappaB kinase beta 





Identification of novel IKKβ inhibitors 13-197 and 25-4 
IKKβ activated by phosphorylation of its two T loop serine residues is found in 
nearly 50% of surgical tumor specimens but in only approximately 10% of normal tissues. 
Furthermore, there is a perfect correlation between the presence of the pro-inflammatory 
cytokine TNF and phosphorylation of IKKβ, in addition to a perfect correlation between 
phosphorylation of IKKβ and phosphorylation of its substrate, IκB, in these tissues.58 This 
suggests IKKβ is constitutively activated in tumor specimens in response to TNF in the 




Figure 4: Comparison of the open human IKKβ dimer (top) and 
the xIKKβ closed dimer (bottom). A) Human IKKβ forms a face-
to-face KD dimer with another dimer while B) xIKKβ forms a closed 
dimer of dimers. This research was originally published in J. Biol. 
Chem. Liu, S. et al. Crystal structure of a human IkappaB kinase 
beta asymmetric dimer. J. Biol. Chem. 2013; 288: 22758-67.47 
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As such, we sought to develop inhibitors of the NF-κB pathway. We took two routes 
to accomplish this task. First, we 
screened a library of novel small 
molecules for activity against TNF-
induced IKKβ-mediated NF-κB-
driven transcription and identified 
the quinoxaline urea analog 13-197 
as an inhibitor of the NF-κB pathway 
(Figure 7A).126-128 The quinoxaline 
core of 13-197 is considered a 
privileged scaffold as it is found in a 
number of natural products and 
commercially available drugs such 
as the smoking cessation drug 
Varenicline.129 A follow-up kinase 
screen and mechanism-based 
studies revealed that 13-197 
inhibits NF-κB-driven transcription 
by targeting the kinase IKKβ. As 
information regarding the 
prevalence of TNF in the tumor 
microenvironment and consequent 
activation of the NF-κB pathway has implicated over-activation of IKKβ, and not just 
mutation of IκB or amplification or rearrangement of NF-κB subunits, in the constitutive 
activation of the NF-κB pathway, we tested this small molecule for anticancer activity in 
 
 
Figure 5: Comparison of the Xenopus laevis 
and human IKKβ dimers. A) The activation 
loop of xIKKβ (which is shown in red) is far from 
the activation loop of the neighboring protomer. 
B) The KD of the nonphosphorylated human 
IKKβ molecule is close to the active site of the 
activated KD. This orientation may facilitate the 
trans-phosphorylation of an unactivated KD by 
an active kinase domain. This research was 
originally published in J. Biol. Chem. Liu, S. et 
al. Crystal structure of a human IkappaB kinase 




cell lines and an orthotopic mouse model of pancreatic cancer and saw the small molecule 
was active without inducing toxicities associated with known IKKβ inhibitors. 
The small molecule is a non-ATP competitive inhibitor of IKKβ and initial studies 
suggest 13-197 probably best occupies a pocket that is formed following the activation of 
resting IKKβ. Upon phosphorylation of S177 and S181 of IKKβ and activation of the 
kinase, the kinase undergoes a conformational change that creates potential binding sites 
that can be targeted by small molecules. Small molecules targeting these sites are likely 
to target the activated but not inactive form of the kinase.47 We believe 13-197 exhibits 
anticancer activity without inducing toxicity by inhibiting an activated form of IKKβ while 
allowing the transient activation of the protein. We hypothesize that constitutive activation 
of the NF-κB pathway by TNF results in the sustained activation of the IKK complex in 
many solid tumors (See Figure 6 for model). We believe this sustained stimulation of IKKβ 
results in the accumulation of phosphorylated IKKβ that can be targeted by 
pharmacological inhibitors to allow successful targeting of the kinase for anticancer 
therapy. In our model, TNF in the tumor microenvironment drives the chronic activation 
of IKKβ by phosphorylation of the kinase’s T loop serine residues (S177 and 181). Once 
phosphorylated on the T loop serine residues, IKKβ exhibits high activity and 
autophosphorylates a stretch of serine residues on its C-terminus, which provides docking 
sites for phosphatases that dephosphorylate the T loop serine residues to inactivate the 
kinase. Phosphorylation of the T loop serine residues of IKKβ is detectable minutes 
following stimulation with TNF,125 making the transient activation of IKKβ very rapid. 
Furthermore, as phosphorylation of the C-terminal serine residues is an intramolecular 
event, this process should also occur quickly. However, the dephosphorylation of the 
kinase by phosphatases is a bimolecular event and is thus the rate-limiting step in the 
deactivation of IKKβ. Therefore, we propose that a hyperphosphorylated form of IKKβ in 
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which the T loop serine residues and C-terminal serine residues are phosphorylated 
accumulates in cancer. We hypothesize that this form of IKKβ is an ideal target for 
anticancer therapy and targeting this form will allow the transient activation of IKKβ that is 
required for normal immune functioning but will block the chronic activation of IKKβ that 
drives tumorigenesis. As such, we tested small molecule 13-197 for activity against 
activated IKKβ and preliminary experiments indicate the small molecule indeed targets 
activated IKKβ. 
In our second approach to designing an inhibitor of the NF-κB pathway, we hoped 
to target IKKβ by designing a small molecule inhibitor that featured the -methylene--
butyrolactone of the known IKKβ and NF-κB subunit p65 inhibitor parthenolide.122, 130 After 
 
Figure 6: Model for this progressive phosphorylation of IKKβ and its 
accumulation in cancer tissues. TNF in the tumor microenvironment drives the 
chronic activation of IKKβ by phosphorylation of the kinase’s T loop serine residues. 
Once phosphorylated on the T loop serine residues, IKKβ exhibits high activity and 
phosphorylates a stretch of C-terminal serine residues, which provides docking sites 
for phosphatases that dephosphorylate the T loop serine residues to inactivate the 
kinase. Phosphorylation of the T loop serine residues of IKKβ is very rapid. 
Furthermore, as phosphorylation of the C-terminal serine residues is an 
intramolecular event, this process also occurs quickly. However, the 
dephosphorylation of the kinase by phosphatases is a bimolecular event and is thus 
the rate-limiting step in the deactivation of IKKβ. 
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screening a small library of -methylene--butyrolactones against TNF-induced IKKβ-
mediated NF-κB-driven transcription, we identified the small molecule 25-4 (Figure 7B) as 
an inhibitor of NF-κB-driven transcription.131 This small molecule likely targets surface-
exposed C179 of IKKβ and a surface-exposed cysteine residue in NF-κB, likely C38. 
C179, found in the activation loop of IKKβ, is primed for targeting as it sits between serine 
residues 177 and 181, which are phosphorylated to drive the activation of IKKβ.125, 132 
Cysteine residue 38 in NF-κB plays an important role in the protein’s activation of gene 
expression.133  
As briefly mentioned, parthenolide, a sesquiterpene lactone natural product, also 
targets IKKβ and NF-κB subunit p65 through covalent interaction with the sulfhydryl group 
of C179 of IKKβ and C38 of NF-κB.122, 130, 134, 135 The sulfhydryl groups on C179 of IKKβ 
and C38 of NF-κB covalently react with the Michael acceptor in the -methylene--
butyrolactone moiety of parthenolide, which results in the inhibition of the NF-κB 
pathway.122 Parthenolide has displayed anticancer effects in cervical, breast, lung and 
pancreatic cancers and potentiates the effects of clinically approved chemotherapeutics 
such as gemcitabine, paclitaxel and cisplatin.136-138 Despite these remarkable activities, 
Parthenolide suffers from poor water solubility, is unstable under acidic and basic 
conditions and affords few opportunities for optimization due to structural complexity.139, 
140 Parthenolide’s core structure features a highly functionalized, fused cyclodecane 
lactone that is decorated by an epoxide, an E-alkene and four stereocenters and is trans 
fused to an -methylene--butyrolactone.134 Recently, the first total synthesis of 
Parthenolide was reported.141 This complicated structure limits our ability to easily 
generate the analogs that would allow us to perform the extensive structure activity 
relationship (SAR) studies required to identify compounds with improved biological activity 
and drug-like properties. 
34 
 
Our main goal in our project with 25-4, which inhibits the NF-κB pathway by 
covalently binding to IKKβ and NF-κB, was to identify a highly modifiable core that, like 
parthenolide, contains the -methylene--butyrolactone moiety and is expected to target 
proteins through covalent interactions via its Michael acceptor. In our preliminary studies, 
25-4 has been shown to inhibit phosphorylation of the IKKβ substrate IκB, reduce cancer 
cell viability and induce caspase 3/7 activation and PARP cleavage in cancer cell lines. 
Furthermore, it has reduced tumor growth in an orthotopic model of ovarian cancer. Very 
importantly, the small molecule did not exhibit overt toxicity at therapeutic doses in mice 
and its structure affords us an opportunity to make structural changes that will allow us to 
conduct SAR studies that will potentially identify more potent and more specific inhibitors 
of the NF-κB pathway. As such, this project has identified a core that may be suitable for 
use as an IKKβ and/or p65 inhibitor and future studies will be aimed at improving the drug-
like properties and specificity of the small molecule and identifying the form of IKKβ 
targeted by this non-toxic IKKβ inhibitor. 
Treatment of cancer cells with small molecules 13-197 and 25-4 resulted in 
impaired IκB phosphorylation, decreased cancer cell viability and increased apoptosis in 
cancer cell lines and decreased tumor growth and metastasis in orthotopic mouse models 
of cancer without inducing the toxicities associated with commercially available IKKβ 
inhibitors. We hypothesize their lack of toxicity is due to selective inhibition of 
phosphorylated IKKβ. Their selective inhibition of phosphorylated IKKβ allows the 
transient activation of IKKβ prior to inhibition. Allowing this transient activation of IKKβ 
appears to diminish toxicity in normal tissues while inhibition of sustained IKKβ activation 
appears sufficient for induction of cancer cell death, making phosphorylated IKKβ an 
attractive target for cancer drug discovery. The studies presented in this dissertation have 
been aimed at establishing 13-197 and 25-4 as small molecule inhibitors of IKKβ and have 
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identified functional groups key for their activity. Future studies will be aimed at 
determining if and how the small molecules selectively target phosphorylated forms of 
IKKβ and exploring the off-target effects of these small molecules. 
 
 
Figure 7: Small molecules 13-197 and 25-4. A) The quinoxaline urea 13-197 and 
B) the spirocylic -methylene--butyrolactone 25-4. Small molecule 13-197 was 
developed by Drs. Qianyi Chen, Rajkumar Rajule, Sandeep Rana and Yogesh 
Sonawayne.126-128 25-4 was developed by Dr. Sandeep Rana. 131 
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Chapter 4: Materials and General Methods  
Chemicals and reagents 
The quinoxaline urea analog 13-197 was synthesized and purified (>98%) as previously 
described.126, 127  
The -methylene--butyrolactone 25-4 and its analogs were synthesized and purified as 
previously described.131 HPLC-grade methanol was obtained from Fisher Scientific (Fair 
Lawn, NJ, USA). Triethanolamine (≥99.5%) was obtained from Sigma Life Science (St. 
Louis, MO, USA). Tris(2-carboxethyl)phosphine hydrochloride (98%) was obtained from 
Alfa Aesar (Ward Hill, MA, USA). 5-TAMRA azide was obtained from Lumiprobe 
(Hallandale Beach, Florida, USA). TAMRA-Azide-biotin was obtained from Click 
Chemistry Tools (Scottsdale, AZ, USA). CuSO4·5H2O (≥98%) VWR International (West 
Chester, PA, USA. Tris[(1-benzyl-1-H-1,2,3-triazol-4-yl)methyl]-amine (97%) was 
obtained from Aldrich (St. Louis, MO, USA). 
Cell lines and culture conditions 
Human pancreatic cancer cell lines MIAPaCa-2, PANC-1, Capan-2 and SUIT-2, cervical 
cancer cell line HeLa and breast cancer cell line MDA-MB-231 were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) high glucose supplemented with 10% fetal bovine 
serum (FBS). Human embryonic kidney cells (HEK cells) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) low glucose supplemented with 10% fetal FBS. Human 
ovarian cancer cell line A2780 and pancreatic cancer cell lines Capan-2 and Hs766T were 
cultured in Roswell Park Memorial Institute-1640 medium (RPMI) supplemented with 10% 
FBS. Human lung cancer cell line luciferase A549 (generous gift from Prof. Brasier, 
University of Texas Medical Branch, Galveston, TX) was cultured in DMEM high 
supplemented with 10% FBS and 100 µg/mL hygromycin B. IKK knock-out (-/-) and IKKβ 
knock-out (-/-) mouse embryonic fibroblast (MEF) cells (generous gift from Prof. I. Verma, 
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Salk Institute) were grown in DMEM high medium with 10% FBS and 1% Pencillin-
Streptomycin as were wild-type MEFs. 
Cell lysis 
Cytoplasmic fractions were generated by harvesting cells on ice in Buffer A (10 mmol/L 
HEPES, 10 mmol/L KCl, 0.1 mmol/L EDTA, and 2 mmol/L DTT) containing protease and 
phosphatase inhibitors. The cells were allowed to swell on ice for 30 min and 1.25% NP-
40 was added and the samples were centrifuged in the cold. The resulting supernatant 
was transferred to a new tube and designated as the cytoplasmic fraction. To obtain 
nuclear fractions, Buffer C (20 mM HEPES, 420 mM NaCl, 5 mM EDTA, 5 mM DTT, 10% 
glycerol) containing protease and phosphatase inhibitors was added the remaining pellet.  
The samples were incubated on ice with intermittent agitation over a period of 30 min and 
were then centrifuged in the cold.  The resulting supernatant was designated the nuclear 
fraction. All samples were stored at -80°C until needed. 
Whole cell lysates were generated by harvesting cells on ice in HNTG lysis buffer (20 mM 
HEPES, pH 7.5, 25 mM NaCl, 0.1% Triton X-100, 10% glycerol) containing protease and 
phosphatase inhibitors. The cells were allowed to swell on ice for 30 min and the samples 
were centrifuged in the cold. The resulting supernatant was transferred to a new tube and 
designated as a whole cell lysate. All samples were stored at -80°C until needed. 
For click chemistry, cells were harvested via scraping in 1X PBS with protease and 
phosphatase inhibitors and sonicated for 15 min. Lysates were spun and the soluble 
fraction (supernatant) was collected and transferred to a new tube. All samples were 
stored at -80°C until needed. 
Western blotting 
Cytoplasmic fractions or whole cell lysates were prepared from control and treated cells 
as described above. The cell lysates (25 µg) were resolved in 4% to 20% denaturing 
polyacrylamide gel (Bio-Rad) and transferred to polyvinylidene difluoride (PVDF) 
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membranes (Millipore). The membranes were incubated with the following antibodies: 
rabbit anti-p-IKK/β (Cell Signaling 2697), rabbit anti-IKKβ (abcam EPR6043), rabbit anti-
IκB (Cell Signaling 4812), mouse antiphospho-IκB (Cell Signaling 9246) or mouse anti-
PARP (Cell Signaling 9542). Internal loading control for cytoplasmic fractions and whole 
cell lysates used mouse anti-tubulin (Cell Signaling 3873) or GAPDH (Santa Cruz 
Biotechnology, Inc. sc-25778). These primary antibodies were incubated with horseradish 
peroxidase–conjugated specific secondary antibodies. The signals were developed by 
using Amersham ECL Prime Western Blotting Detection Reagent (General Electric 
Healthcare Life Sciences). 
Data processing and statistical analysis  
P-values were determined using one way ANOVA in SigmaPlot and values < 0.05 were 
considered significant. 
IC50 values were derived from plotting cell viability against drug concentration and curve-
fitting the data using a four-parameter logistic curve in SigmaPlot. 
κB-luciferase assay 
A549 luciferase cells were seeded in white 96-well plates at a density of 50,000 cells per 
well and incubated overnight. Cells were then treated with the indicated concentrations of 
drugs for 2 hours. Cells were then stimulated with 20 ng/mL TNF (Panomics) for 3 hours. 
AlamarBlue (abSerotec) was added (which served as a control for seeding and viability) 
and the cells were incubated for 3 additional hours. ONE-Glo Luciferase reagent 
(Promega) was added to each well and cells were incubated at room temperature for an 
additional 10 min before luminescence was measured at 1000 ms integration on a 






For click chemistry with purified proteins, purified IKKβ or p65 (250 ng in a total volume of 
200 µL) was incubated with 10 µM 31-036 for 1 hour. 5-TAMRA azide (Lumiprobe) (0.1 
mM from a 1 mM DMSO stock) and click chemistry reagents (1 mM tris(2-carboxyethyl)-
phosphine hydrochloride (TCEP) from 50 mM stock in water, 1 mM CuSO4·5H2O from a 
freshly prepared 50 mM stock in water, and 0.1 mM tris[(1-benzyl-1-H-1,2,3-triazol-4-
yl)methyl]-amine (TBTA) from 10 mM stock in DMSO) at a total volume of 48 µL were 
added for 1 hour and then the reaction was quenched with ice cold methanol and stored 
at -20°C to precipitate. The resulting precipitate was spun and the methanol was removed. 
The pellet was resuspended in 4% SDS buffer (4%SDS, 150 mM NaCl, 50 mM TEA pH 
7.4) and 2X sample buffer (20% glycerol, 0.2% bromophenol blue, 1.4% β 
mercaptoethanol) to 1X. Samples were resolved on 4% to 20% denaturing polyacrylamide 
gel (Bio-Rad) and visualized using the Typhoon 9410 Variable Mode Imager. 
For click chemistry in cells, cells were treated with the indicated concentration of 31-036 
for 1 h and then cells were harvested as described above. 200 µg of total protein in 152 
µL total volume was incubated with 48 µL of the same click chemistry cocktail described 
above to give 200 µL total volume. Click chemistry was continued as described above. 
Cellular viability assay 
Cellular viability was determined by alamarBlue Cell Viability Assay (Life Technologies) or 
PrestoBlue Cell Viability Assay (Life Technologies) according to manufacturer’s 
instructions. MIAPaCa-2, A2780, MDA-MB-231, Hs766T, AsPC-1, luciferase A549,  SUIT-
2 and PANC-1 cells were incubated with compound in at least duplicate in a 96-well plate 
and then incubated for 24, 48 or 72 hours at 37°C. AlamarBlue solution was added to each 
well (equal to 10% volume of the medium in the well) and incubated for 3 hours at 37°C 
or PrestoBlue solution was added to each well (equal to 10% volume of the medium in the 
well) and incubated for 30 minutes at 37°C. The fluorescence of the solution was 
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measured at 560 nm excitation and 590 nm emission using SpectraMax M5e fluorescence 
plate reader. Dose–response curves were evaluated using the National Cancer Institute 
(NCI) algorithm: Tz = number of control cells at time t0, C = number of control cells at time 
t, and T = number of treated cells at time t; 100 × [(T - Tz)/(C - Tz)]. 
PARP cleavage 
Cells were treated as indicated and harvested by collecting media, trypsinizing cells, and 
centrifuging to obtain a combined cell pellet from all steps. Cells were lysed in radio 
immuno precipitation assay (RIPA) buffer (150 mM NaCl, 1.0% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0) and protein content was 
resolved on 4% to 20% denaturing polyacrylamide gel (Bio-Rad). PARP cleavage was 
determined via Western blotting using anti-PARP antibody. 
Caspase 3/7 assay 
3,000 SKOV3 cells/well were plated in a white, clear bottom, sterile 96 well dish in 95 µL 
and incubated overnight. The next day, cells were treated with 5 µL compounds to yield 
the final drug concentration indicated. Cells were incubated with compound for 24 h. 
AlamarBlue was added to each well and cells were incubated for another 3 hours. 
Fluorescence (560ex/590em) was measured on the SpectraMax M5
 e plate reader. 110 µL 
Caspase Glo-3/7 reagent was added to each well and mixed by the plate reader at 300-
500 rpm for 30 seconds. The plate was incubated at room temperature for 1 h. 
Luminescence was measured on the SpectraMax M5 e plate reader. 
Colony formation assay 
HeLa cells were plated in 6-well plates at a density of 500-1000 cells per well and cultured 
for 24 h, followed by drug treatment for 48 h at 37°C. DMSO was used as a control. Then, 
the supernatant fluid was replaced with fresh medium and the cells were cultured for 7 d. 
Cells were washed twice with PBS and then fixed with methanol for 15 m, followed by 
0.1% crystal violet staining for 30 min at room temperature. Then, crystal violet was 
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carefully removed by immersing the plates in tap water. The plates were then air-dried at 
room temperature for colony counting, where colonies with more than 50 cells were 
counted. 
Immunohistochemistry analysis 
Hematoxylin and eosin staining of ovarian tumor tissues was performed by UNMC’s 
Tissue Science Core Facility to identify tissue areas containing tumor. One core from each 
tumor was arranged into a tumor microarray and slides were generated from the 
microarray. The resulting slides were stained with antibody directed Mcl-1 using Leica 
bond polymer refine detection kit according to manufacturer's instructions (Leica 
Microsystems Inc.). Briefly, the ovarian tumor tissue sections were incubated with rabbit 
anti-Mcl-1 primary antibody (Santa Cruz Biotechnology, Inc. sc-819). Pictures were 
captured by using Coreo Au slide scanner (Ventana Medical Systems Inc.). From each 
image, a representative screen shot was captured at 40X magnification. Quantification of 





Chapter 5: Evaluation of small molecule 13-197  
Introduction to 13-197 
13-197 was originally identified as a small molecule capable of inhibiting growth in 
a growth inhibition screen conducted with a panel of cell lines including A549 lung cancer 
cells, AsPC-1 pancreatic cancer cells, HT29 colon cancer cells, MDA-MB-231 breast 
cancer cells, PC3 prostate cancer cells, SKOV3 ovarian cancer cells and U-2 OS bone 
sarcoma cells. 13-197 was shown to induce caspase 3/7 activation in MDA-MD-231, PC3 
and HeLa cell lines and PARP cleavage in HeLa cells in a Mcl-dependent manner.126, 127  
To further study the apoptotic effects of 13-197, MIAPaCa-2 pancreatic cancer 
cells were treated with 13-197 and apoptosis was measured using the live/dead assay 
(Figure 1A). Treatment with 13-197 resulted in 4X more apoptosis in treated cells than in 
 
Figure 1: 13-197 blocks cell cycle progression and induces 
cell death in MIAPaCa-2 cells. A) Treatment with 13-197 led to 
increased apoptosis in MIAPaCa-2 cells as measured by the 
live/dead cellular assay. B) Treatment with 13-197 led to an 
increase in the number of cells in the G1 phase of the cell cycle 
and reduced levels of E2F, PCNA and Cyclin D1. Reproduced 
from ref 128 
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control cells. Subsequent studies demonstrated induction of cell cycle arrest upon 
treatment with 13-197 (Figure 1B, left). These studies also showed reduced levels of the 
cell cycle markers E2F, PCNA and Cyclin D1 (Figure 1B, right), demonstrating that 13-
197 inhibits MIAPaCa-2 cell growth through induction of G1 arrest.128 
As the NF-κB pathway is known to control the transcription of genes that regulate 
growth, apoptosis and the cell cycle,142, 143 processes which are all affected by 13-197, the 
small molecule was screened for activity in this pathway. For the screen, a lung cancer 
cell line (A549) that was specifically designed to express firefly luciferase under control of 
an NF-κB-driven promoter was used to monitor the activity of NF-κB in response to TNF 
(Panomics). Cells were treated with the compounds for 2 h and then TNF was added to 
cells to stimulate the NF-κB pathway for an additional 6 h. Under multiplexing conditions 
the cells were assayed for viability using AlamarBlue (Ab Serotec) and TNF-induced 
IKKβ-mediated NF-κB-driven transcription using the ONE-Glo luciferase system 
(Promega). Treatment with 13-197 
resulted in a 75% decrease in NF-κB-
driven transcription compared to 
DMSO-treated cells. 
As NF-κB is known to regulate 
invasion and metastasis,144 the ability of 
13-197 to block invasion and migration 
of MIAPaCa-2 cells was also measured 
(Figure 2). 13-197 inhibited both the 
invasion and migration of MIAPaCa-2 
cells by about 50%, demonstrating that 
13-197 may inhibit both the growth of primary tumors and their metastasis.  
 
Figure 2: 13-197 inhibits invasion and 
migration of cancer cells. Treatment with 
13-197 led to decreased invasion and 
migration of MIAPaCa-2 cells. Reproduced 
from ref 128 
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With this building evidence that 13-197 could serve as an inhibitor of viability, cell 
cycle progression and invasion and migration of cancer cells, we decided to further 
investigate 13-197’s mechanism of action and its effects on cancer cells via its inhibition 





13-197 was identified as an inhibitor of TNF-induced IKKβ-mediated NF-κB-
driven transcription in luciferase A549 cells. In a focused, follow-up screen using the same 
assay, 13-197 and quinoxaline urea analogs were screened for activity against TNF-
induced IKKβ-mediated NF-κB-driven luciferase expression at 20 µM to generate a small 
structure activity relationship (Figure 3). The well-studied NF-κB pathway inhibitor 
parthenolide122 was used as a positive control. Small molecule 13-197 features furan rings 
at the R1 positions and a bromo- substituent at the R2 position. Replacement of the R1 
furan rings with pyridine rings (20-185) resulted in negligible loss of activity. Replacement 
of the R1 furan rings with a methyl group (20-162) had a greater effect on activity. 
 
Figure 3: Subset of a focused library screened to identify inhibitors of TNF-
driven IKKβ-mediated NF-B activation. Quinoxaline analogs were screened for 
activity against the NF-κB pathway at 20 M. The core structure of the analogs 
featured in this screen and the positive control parthenolide is given above the graph 
and the structures for the quinoxaline analogs are given to the right. 
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Furthermore, substitution of the bromo- group at the R2 position of analog 20-162 with 
hydrogen yielded analog 13-123, which 
displayed no activity in the assay.  
A follow-up screen against 318 
kinases identified IKKβ as a molecular 
target of 13-197. The kinase screen 
was outsourced to Reaction Biology 
Corp. 13-197 was screened in 
duplicate against 318 kinases. Six 
kinases were identified as hits based 
on >2 SD (> 95% confidence) from the 
mean of the screen (Figure 4). These 
kinases included ephrin type-A 
receptor 6 (EPHA6), mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), 
IKKβ, never in mitosis A-related kinase 3 (Nek3), serine/threonine protein kinase 25 
(STK25) and tropomyosin receptor kinase A (TrkA). The IC50 values were in the low-M 
range for four of the six kinases inhibited by 13-197. The kinases TRKA and IKKβ had the 
lowest IC50 values at 1.9  0.2 M and 3.0  0.1 M respectively. 
As IKKβ phosphorylates IκB upon stimulation with TNF, we hypothesized that 
treatment with 13-197 should block IκB phosphorylation. To test this, HEK293 cells were 
pretreated with DMSO or 13-197 for 2 h and then stimulated with 20 ng/mL TNF for 
increasing times (0, 5, 10, 15, 20, 30, 45, 60, 75, 90 and 120 min) to drive IKKβ activation 
and IκB phosphorylation and degradation. Cells were harvested and the cytoplasmic 
fraction was probed for phosphorylated and total IκB to measure IKKβ activity (Figure 5). 




Figure 4: 13-197 inhibits IKKβ activity. A 
follow-up kinase screen identified IKKβ as a 
molecular target of 13-197. Reproduced 
from ref 128 
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by the 5 min time point. Thirty minutes after stimulation, most of the IB in the cell had 
been phosphorylated and degraded via phosphorylation-mediated proteasomal 
degradation. As IB is a target gene of NF-κB, IκB re-expression was seen 45 min post-
stimulation. The newly synthesized IκB present at the 45 min time point was again 
phosphorylated by IKKβ. In the presence of 13-197, little inhibition of IκB phosphorylation 
and degradation was seen at the early time points. A similar pattern to DMSO-treated cells 
is seen at the 30 min time point and at 75 minutes post-stimulation re-expression of IκB 
is seen. However, a significant reduction in phospho-IκB levels in comparison to DMSO-
treated lanes is seen at the latest time points. The results of this experiment suggest that 
13-197 does not inhibit the resting form of IKKβ that would persist prior to TNF treatment 
but rather inhibits the phosphorylated form of IKKβ that persists approximately 1 h 
following TNF stimulation. 
To further test the hypothesis that 13-197 inhibits phosphorylated IKKβ and not 
resting IKKβ, we compared the activity of 13-197 to that of the commercially available, 
ATP-competitive IKKβ inhibitor TPCA-1118 (Figure 6). As before, cells were pretreated with 
 
 
Figure 5: 13-197 inhibits phosphorylated IKKβ. HEK293 cells were pretreated 
with DMSO or 13-197 for 2 h and then the NF-κB pathway was stimulated by 
treatment with 20 ng/mL TNF for the times indicated. In DMSO-treated cells, IκB 
is rapidly phosphorylated (5 min) leading to its degradation (30 min). Re-expression 
of IκB occurs by the 45 min time point in DMSO-treated cells and persists through 
the experiment. This newly synthesized IκB is again phosphorylated. In 13-197-
treated cells, a similar pattern is seen through the 30 min time point. Again, at later 
time points, re-expression of IκB is seen. However, this newly synthesized IκB is 
not phosphorylated by IKKβ. 
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compound (13-197 or TPCA-1) and then stimulated with TNF to drive activation of the 
NF-κB pathway. In 13-197-treated cells there is rapid phosphorylation of IκB. However, 
when cells are treated with TPCA-1 a different pattern is seen. In cells treated with TPCA-
1, there is no early phosphorylation of IκB, demonstrating that TPCA-1 inhibits resting, 
unphosphorylated IKKβ and thus inhibits the rapid phosphorylation of IκB seen within 
minutes of TNF stimulation in DMSO- or 13-197-treated cells. These results further 
support the hypothesis that 13-197 preferentially targets phosphorylated IKKβ and 
establishes a unique mechanism of action for the small molecule.  
Since the knockout of IKKβ has been shown to stall the progression of Kras-driven 
pancreatic cancer at PanIN lesions in mice,72 and previous data had shown activity in 
pancreatic cancer cell lines,145 we next decided to explore the role of IKKβ in pancreatic 
cancer cell lines. RIPA whole cell lysates of Hs766T, MIAPaCa-2, Capan-2, Suit-2 and 
AsPC-1 pancreatic cancer cells lines were probed for phosphorylated and activated IKKβ 
(Figure 7). Robust phosphorylation of the kinase was seen in all 5 pancreatic cancer cell 
lines, suggesting that activation of the kinase indeed may play a role in pancreatic cancer. 
 
 
Figure 6: Inhibition of resting IKKβ by TPCA-1 but not 13-197. 
IKK was activated by TNF (20 ng/mL) in HEK293 cells 
pretreated with vehicle, TPCA-1 or 13-197 (20 M). Cell lysates 
were generated at early time points and probed for phospho-IκB, 
total IκB and tubulin. Reproduced from ref128 
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To test if 13-197 would inhibit the activated IKKβ that was seen in the pancreatic 
cancer cell lines, Dr. Vashti C. Bryant and I treated a panel of pancreatic cancer cells with 
13-197 and probed lysates for levels of phospho- and total IκB (Figure 8). Treatment with 
20 µM 13-197 for two hours resulted in decreased phosphorylation of the IKKβ substrate. 
Next, we treated MIAPaCa-2 pancreatic cancer cells with 13-197 and monitored 
phosphorylation of IκB upon treatment with increasing doses of 13-197 or increasing 
exposure to a single concentration of 13-197 (Figure 9A). Additionally, we assessed the 
viability of a panel of cell lines over time using the AlamarBlue assay (Figure 9B and C). 
13-197 inhibited IκB phosphorylation and cell viability at low µM-potency.  
 
Figure 8: 13-197 reduces IκB phosphorylation in pancreatic cancer cell 
lines. Pancreatic cancer cell lines were treated with 13-197 at 20 µM for 2 hours 
and lysates were probed for phosphorylated and total IκB. AsPC1, Capan-2 and 
Hs766T immunoblotting performed by Dr. Vashti C. Bryant. Reproduced from ref128 
 
 
Figure 7: IKKβ is phosphorylated in pancreatic cancer cell lines. Pancreatic 
cancer cell lines were probed for phosphorylated and total IKKβ. Under basal 
conditions, IKKβ is phosphorylated in pancreatic cancer cell lines. This experiment 




Given NF-κB’s role in anti-apoptotic signaling,146 we next investigated 13-197’s 
ability to induce apoptosis in cancer cells through down-regulation of anti-apoptotic 
proteins. To test this, I treated MIAPaCa-2 cells with 13-197 at increasing concentrations 
or for increasing periods of time and probed lysates for Bcl-xL, Mcl-1, survivin and XIAP, 
which are all known target genes of NF-κB.21, 23-25 Dose-dependent decreases in the levels 
of Bcl-xL, survivin, Mcl-1 and XIAP were seen in cells treated with 10 or 20 µM 13-197 for 
2 h (Figure 10, left panel). Furthermore, decrease of Bcl-xL, survivin and Mcl-1 levels was 
time-dependent with Mcl-1 levels decreasing within 30 min of 13-197 treatment (Figure 
10, right panel), suggesting IKKβ may regulate the stability of Mcl-1 via phosphorylation 
of the protein. Overall, this data demonstrates that 13-197 down regulates anti-apoptotic 
proteins in both dose- and time-dependent manners.  
 
Figure 9: 13-197 reduces IκB phosphorylation and viability of pancreatic 
cancer cells. A) Treatment with 13-197 led to decreased expression of P-IκB in 
pancreatic cancer cells. Furthermore, this inhibition of IκB phosphorylation was dose 
dependent. Reproduced from ref128 B) Treatment with 13-197 reduced cell viability in 
a panel of pancreatic cancer cells. C) Representative dose-response curve with 
MIAPaCa-2 cells. Bars represent standard error of the mean for three separate 
experiments conducted at least in duplicate. 
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Due to these promising cell-based results, which demonstrated decreased NF-κB-
driven transcription, decreased phosphorylation of IκB, inhibition of phosphorylated IKKβ 
activity, decreased cell viability and increased apoptosis in cancer cells, small molecule 
13-197 was moved into a mouse model of pancreatic cancer by collaborators, namely Dr. 
Prakash Radhakrishnan.128 An orthotopic mouse model of pancreatic cancer was used to 
investigate 13-197’s anticancer properties in vivo. For this study, MIAPaCa-2 cells were 
orthotopically placed in the pancreas of nude mice and mice were allowed to heal after 
surgery. Tumors were given 2 weeks to grow and were palpable and the end of this period. 
Tumor-bearing mice were randomized and half the animals were treated orally with 150 
mg/kg 13-197 in cremaphor daily while the other half was treated with vehicle control. At 
the end of 30 days the mice were sacrificed and the tumors weights and volumes were 
measured.  
Tumor weights and volumes were reduced by 50% in 13-197-treated animals 
compared to vehicle-treated mice (Figure 11A). Fewer tumor nodules were seen in other 
organs of 13-197-treated animals compared to vehicle-treated animals (Figure 11B), 
which is consistent with our cell-based data demonstrating inhibition of MIAPaCa-2 cell 
growth and invasion and migration. Proliferation index and microvessel density were 
 
Figure 10: 13-197 decrease levels of anti-apoptotic proteins in cancer cells. 
Treatment with 13-197 led to decreased expression of anti-apoptotic proteins Mcl-1, 
Bcl-xL, XIAP and survivin. Reproduced from ref 128 
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measured to assess the number of cells dividing in tumors and as measure of 
angiogenesis, respectively (Figure 11C and D). A reduction of both, as measured by Ki-
67 staining and CD31 staining, respectively was seen in 13-197-treated mice compared 
to vehicle controls. Tumor tissues were scored by a pathologist (Dr. Subodh Lele) and 
decreased inflammation and increased necrosis was seen in 13-197-treated mice (Figure 
11E). The levels of 13-197 in the pancreas, liver and serum were determined at the end 
of the study with the levels being the highest in the liver. Due to the high levels of 13-197 
in the liver, levels of ALT and AST were measured in 13-197- and vehicle-treated mice 
(Figure 11F and G). No difference in the levels of these enzymes were seen between 13-
197- and vehicle-treated mice, indicating an absence of liver toxicity (Figure 11G). 
Macroscopic examination of the organs of 13-197-treated and vehicle-treated mice found 
no obvious toxicities in 13-197-treated animals. Overall, these studies show that 13-197 
is an orally available small molecule that exhibits excellent distribution and reduces tumor 




Figure 11: Treatment with 13-197 reduces tumor burden and metastases in a 
mouse model of pancreatic cancer. A) Tumor weights and volumes in 13-197- and 
vehicle-treated mice at the end of the study. B) Number of animals with tumors and 
number of tumor nodules found in various organs. C) Ki-67 staining. D) CD31+ 
staining. E) Inflammation and necrosis scored by a pathologist (Dr. Subodh Lele). F) 
13-197 levels in the pancreas, liver and serum 18 h after the last treatment. G) AST 
and ALT levels measured in mice at the end of the study. (**P < 0.05). The work 
depicted in this figure was performed by Dr. Prakash Radhakrishnan and 





On-going studies with 13-197 
As other NF-κB pathway inhibitors have shown an ability to chemosensitize cells 
to treatment with the clinical therapeutics gemcitabine114, 115 and paclitaxel,98 we are 
investigating the ability of 13-197 to synergize with these compounds in pancreatic cancer 
cells. To accomplish this goal, I have determined IC50 values for gemcitabine and 
paclitaxel in a panel of pancreatic cancer cell lines (Capan-2, MIAPaCa-2 and SUIT2 cells) 
for which 13-197 sensitivity has already been established (Figure 9, this chapter).  A 
representative dose-response graph for MIAPaCa-2 cells is shown (Figure 12). MIAPaCa-
2, Capan-2 and SUIT-2 cells were sensitive to the clinical inhibitor paclitaxel with IC50s in 
the low (Capan-2 and MIAPaCa-2) or mid (SUIT-2) nM range while all displayed IC50s to 
gemcitabine in the mid µM range. Interestingly, the two cell lines that are not sensitive to 
 
 
Figure 12: IC50 values for paclitaxel and gemcitabine in five pancreatic cancer 
cell lines that are sensitive to 13-197 treatment. A) IC50 values for paclitaxel and 
gemcitabine for a panel of 5 pancreatic cancer cell lines. Representative dose 




treatment with paclitaxel and gemcitabine, AsPC-1 and Hs766t, above 100 µM are 
sensitive to 13-197 at approximately 17 and 14 µM respectively,128 suggesting 13-197 may 
serve as a viable therapeutic for the treatment of pancreatic cancer resistant to current 
clinical inhibitors. 
Using these IC50 values as starting points, we will treat the cells lines with 13-197 
and gemcitabine, 13-197 and paclitaxel or 13-197, gemcitabine and paclitaxel in 
combination at 5X their IC50s, their IC50s and subIC50 concentrations of the clinical inhibitors 
in matrix format to test for possible synergism. CI values will be derived from pancreatic 
cancer cell treatments at the above concentrations for 72 hours. Cell viability will be 
determined via AlamarBlue assay and the fraction of cells dead for each treatment will be 
calculated. These values will be used to calculate combination index (CI) values using 
CalcuSyn and the Chou-Talalay method for calculating CI values. Using this method, a 
combination index will be calculated for a combination treatment based on the fraction of 
cells affected (fraction dead) by a particular treatment. CI values below 1 indicate 
synergism. Additive effects are indicated by a CI value of 1. A value above 1 indicates 
antagonism.147 As other NF-κB pathway inhibitors have shown synergism with 
gemcitabine and paclitaxel,80, 82, 114, 115 we expect to see the same with 13-197.  
Conclusions 
The work presented in this chapter provides evidence that IKKβ is phosphorylated 
and activated in pancreatic cancer cells which leads to the phosphorylation of IB and 
subsequent activation of the NF-B pathway. Treatment of HEK293 cells with the 
quinoxaline urea analog 13-197 results in decreased phosphorylation of IB an hour 
following stimulation with TNF, suggesting 13-197 targets a phosphorylated, activated 
form of IKKβ but not resting IKKβ. In pancreatic cancer cells, 13-197 targets IKKβ to 
regulate transcription through the IKKβ/IB/NF-B pathway, resulting in decreased 
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expression of anti-apoptotic proteins Bcl-xL, Mcl-1, survivin and XIAP and decreased 
viability of cancer cells. Furthermore, 13-197 exhibited low-µM potency in two cell lines 
(AsPC-1 and Hs766T)128 that are resistant to treatment with paclitaxel and gemcitabine. 
Lastly, work with collaborators has shown that 13-197 reduces tumor burden in a mouse 
model of pancreatic cancer without inducing toxicities associated with known IKKβ 
inhibitors. Further studies with the small molecule will be aimed at further refining the small 




Chapter 6: Evaluation of small molecule 25-4 
Results 
As mentioned previously, the small molecule 25-4 was designed to feature the 
same -methylene--butyrolactone motif found in the natural product parthenolide, which 
has been shown to have activity against the NF-κB pathway despite its limited success in 
clinical trials.122, 124 The available SAR with parthenolide analogs clearly shows that the 
Michael acceptor in the -methylene--butyrolactone is critical for activity against the NF- 
κB pathway.117 
Here we generated a biased library that features the -methylene--butyrolactone 
core and tested this library for activity against TNF-induced IKKβ-mediated NF-κB-driven 
transcription activation again using our cell-based luciferase assay (Figure 1). At 20 µM, 
small molecule 25-4 displayed high activity in the screen, inhibiting NF-κB-driven 
transcription by nearly 75%. Reduction of the double bond of the ,β-unsaturated lactone 
resulted in compound 25-18, which showed no activity in the screen. 28-090, which is an 
acyclic analog of 25-4, showed reduced activity compared to 25-4, suggesting the ,β-
unsaturated lactone and rigidification of the Michael acceptor are necessary for the high 
activity of 25-4. Substitution of the hydrogen at the R1 position with a methyl group resulted 
in small molecule 28-097C, which showed activity comparable to that of 25-4 in the assay. 
28-097A, which is an acyclic version of 28-097C, showed reduced activity in the assay, 
again indicating that rigidification of the Michael acceptor is a favorable feature. 
Compounds 28-131, 28-138 and 28-171 feature the same hydrogen at the R1 position as 
25-4 but feature substitutions at the R3, R2 and R4, and R5 positions, respectively. 28-
131 which features the iodo- substitution at R3 showed a moderate decrease in activity 
while substitution with methyl groups at the R2 and R4 positions (28-138) or a phenyl 
substitution at the R5 position (28-171) resulted in activity comparable to that of 25-4. 
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Overall, these SAR studies showed that the presence and rigidification of the Michael 
acceptor in the ,β-unsaturated lactone were key for activity.  
To confirm that rigidification indeed resulted in increased activity and to determine 
if the Michael acceptor is critical for activity, we further compared the activity of 25-4, the 
reduced compound that lacks the Michael acceptor (25-18) and the acyclic compound 28-
090 to that of parthenolide and a reduced parthenolide analog that lacks the Michael 
acceptor (Figure 2A). Consistent with previous reports, parthenolide showed more than 
95% inhibition while the reduced version was much less active and only exhibited 
approximately 20% inhibition, demonstrating that the Michael acceptor in parthenolide is 
critical for NF-κB inhibitory activity (Figure 2B).11 Similarly the reduced analog 25-18 that 




Figure 1: Novel -methylene--butyrolactone analogs exhibit activity against 
the NF-B pathway. Inhibition of TNF-induced IKK-mediated NF-B activity by the 
-methylene--butyrolactone analogs. The core structure of the compounds featured 
in the focused library of -methylene--butyrolactone analogs and parthenolide is 
above the graph while each analog’s structure can be found to the right. Library 
synthesized by Dr. Sandeep Rana. 
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corresponding analog with the Michael acceptor (25-4). Importantly the acyclic analog with 
the Michael acceptor (28-090) was approximately 2-fold less active than the cyclized 
version, suggesting that rigidification indeed increases activity against the NF-κB pathway.  
In a follow-up dose-response 
study, 25-4 had low M (IC50 ~ 
4 M) inhibitory activity in the 
TNF-induced IKKβ-
mediated NF-κB-driven 
transcription activity assay 
(Figure 2C). Overall, these 
studies identified compound 
25-4 with the -methylene--
butyrolactone as a potent NF-
κB inhibitor. Like parthenolide, 
the NF-κB inhibitory activity of 
25-4 requires the Michael 
acceptor. Additionally, 
rigidification of the Michael 
acceptor of 25-4 increases its NF-κB inhibitory activity. 
We next used click chemistry, which is emerging as a powerful technique for 
determining the targets of covalent small molecules,148 to determine if 25-4 does indeed 
bind irreversibly to the parthenolide targets IKKβ and NF-κB.122, 130 For these studies, the 
25-4 analog 31-036 (Figure 3), which is 25-4 with an alkyne handle at the R1 position, was 
used. The alkyne handle on 31-036 reacts with the azide handle on TAMRA-azide to 
covalently link the two, thereby tagging 31-036 and its target proteins with a fluorescent 
 
Figure 2: Focused SAR with parthenolide, reduced 
parthenolide and 3 analogs. A) Structure of 
parthenolide, reduced parthenolide and 3 analogs B) 
Evaluation of the above inhibitors in the TNF-induced 
IKKβ-mediated NF-κB-driven transcription assay 
demonstrates the importance of the Michael acceptor 
and rigidification C) Dose-dependent inhibition of NF-
κB activity by 25-4. 25-4, 25-18 and 28-090 




rhodamine tag. Recombinant IKKβ and NF-κB were incubated with 31-036 for 1 h at room 
temperature. Rhodamine azide and click reagents were added to the reaction mixture and 
incubated for an additional hour. At the end of the second hour the mixture was subjected 
to SDS-PAGE and the gel was imaged using the Typhoon 9410 Variable Mode Imager, an 
imager that produces digital images of fluorescent samples. The data summarized in 
Figure 3A shows fluorescent bands at molecular weights that correspond to IKKβ and NF-
κB (with a 14 amino acid C-terminal truncation), demonstrating that 31-036 is a covalent 
inhibitor of IKKβ and NF-κB. 
To determine if covalent binding to IKKβ results in the inhibition of the kinase 
activity of IKKβ, MBA-MD-231 breast cancer cells were incubated with 25-4, 25-18, 28-
090, 28-097A and 28-097C (Figure 3B). The cells were lysed and the proteins were 
separated by SDS-PAGE, transferred to a membrane and probed with total and phospho-
IB antibody. Since IB is a substrate of IKKβ, inhibition of the kinase activity of IKKβ 
 
 
Figure 3. 25-4 binds IKKβ and NF-κB to block IKKβ-mediated NF-κB activation. 
A) Schematic of click chemistry used to demonstrate covalent binding of 31-036 to 
IKKβ and NF-κB. B and C) Inhibition of IKKβ kinase activity determined by Western 
blot analysis in MBA-MD-231 breast cancer cells and MIAPaCa-2 pancreatic cancer 
cells. 31-036 synthesized by Dr. Sandeep Rana. 
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should result in reduced IB phosphorylation. Indeed we observed complete inhibition of 
IB phosphorylation in cells treated with 25-4 but no inhibition of IB phosphorylation 
in cells treated with the reduced compound 25-18 that lacks the Michael acceptor. The 
acyclic analog 28-090 showed partial inhibitory activity, which confirms that rigidification 
of the Michael acceptor indeed results in increased inhibition of IKKβ. Furthermore, 28-
097C showed activity while its acyclic version, 28-097A, did not, supporting the 
observation that rigidification of the Michael acceptor is required for activity and confirming 
the results of our luciferase assay.  
Studies with 25-4 demonstrated that the small molecule inhibits phosphorylation 
of IκB in a dose-dependent manner in MIAPaCa-2 cells (Figure 3C). Cells were 
incubated with increasing doses of 25-4 or 25-18 for 2 h. Cells were harvested and 
immunoblotting with anti-phospho- and total IκB antibodies was performed. 25-4 
treatment, but not 25-18 treatment, reduced levels of IκB phosphorylation, providing 
further evidence that 25-4 targets IKKβ while 25-18 does not display activity. 
To determine if inhibition of the IKKβ-NF-κB pathway translates to anticancer 
activity, MDA-MB-231 and MIAPaCa-2 cancer cell lines were subjected to increasing 
concentrations of the IKKβ inhibitors for 3 days and the viability of the cells was assessed 
using PrestoBlue dye. The IC50 values for the IKKβ inhibitors were derived by curve fitting 
the data. 25-4 showed dose- and time-dependent inhibition of cancer cell growth while 25-
18 did not (Figure 4A and 4B) again demonstrating that the Michael acceptor is critical for 
anticancer activity. Furthermore, we subjected a panel of cancer cell lines to treatment 
with 25-4, 25-18 and three previously reported IKKβ inhibitors (13-197, Bayer VIII and 
TPCA-1). Importantly, the growth inhibitory activity of 25-4 was comparable to known IKKβ 





Figure 4: 25-4 decreases cancer cell growth. Dose-response studies with 25-
4 and 25-18 in A) MDA-MD-231 and B) MIAPaCa-2 cells demonstrate that 25-4 
dose- and time-dependently reduces cell viability of cancer cells while the small 
molecule lacking the Michael acceptor (25-18) does not. 
IKKβ inhibitor Cancer cell line IC50 (M) 
25-4 MIAPaCa-2 (Pancreas) 1.2 ± 0.2 
25-4 MDA-MB-231 (Breast) 5.6 ± 0.9 
25-4 A2780 (Ovarian) 2.3 ± 1.4 
25-4 A2780 Cisplatin-resistant (Ovarian) 3.01 ± 1.1 
13-197 MIAPaCa-2 (Pancreas) 1.9 ± 0.6 
13-197 MDA-MB-231 (Breast) 2.1 ± 0.2 
Bayer VIII MIAPaCa-2 (Pancreas) 7.3 ± 0.7 
Bayer VIII MDA-MB-231 (Breast) 8.4 ± 1.2 
TPCA-1 MIAPaCa-2 (Pancreas) 1.8 ± 0.7 
TPCA-1 MDA-MB-231 (Breast) 6.6 ± 1.9 
Table 1: Inhibition of cancer cell growth by 25-4 and known IKKβ inhibitors. 25-
4 inhibits the growth of cancer cells with IC50 values comparable to those of 
commercially available IKKβ inhibitors. IC50 values for 13-197 in MDA-MB-231 cells 
and IC50 values for Bayer VIII and TPCA-1 were determined by Smitha Kizhake. 
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Tian Zhou next helped us determine the ability of 25-4 and 25-18 to block colony 
formation using a clonogenic assay. Cells were sparsely plated and allowed to grow in the 
presence or absence of 25-4 or 25-18 for 7 days. Colonies were then stained using crystal 
violet and quantified (Figure 5A and B). In plates treated with 25-4 we observed a dose-
dependent decrease in the number of colonies while we saw no such effect with 25-18. 
As the NF-κB pathway controls the transcription of many genes that regulate 
apoptosis, we evaluated the ability of 25-4 and 25-18 to induce caspase 3/7 (Figure 5C) 
and PARP cleavage (Figure 6), two key events during apoptosis,149 in cancer cell lines. 
Furthermore, we studied the ability of 25-4 to sensitize cells to treatment with cisplatin as 
platinum-based chemotherapeutics are the first line of treatment for many cancers, 
including ovarian cancer.150 In cells treated with 25-4 we observed modest induction of 
caspase 3/7 cleavage by itself and increased induction of caspase 3/7 cleavage in the 
 
Figure 5: 25-4 inhibits colony formation and induces caspase 3/7 activation in 
cancer cells. (A and B) Dose-dependent effects on colony formation of cervical 
cancer cells (HeLa) by 25-4 and 25-18. (C) Caspase 3/7 activity induced by 25-4, 
cisplatin and the combination in SKOV3 ovarian cancer cells. Tian Zhou performed 
the clonogenic assay pictured in A and B. 
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presence of a cisplatin. This is consistent with reports that implicate activation of NF-κB in 
chemoresistance. We also observed decreased/cleaved PARP in cells treated with 25-4. 
Importantly we observed no such effects in 25-18-treated cells. These studies clearly 
demonstrate that the biological effects induced by 25-4 are through the Michael acceptor 
functionality. 
Due to these promising cell-based results, we next collaborated with investigators 
at Henry Ford Hospital to investigate if these anticancer effects in cell lines translate to 
mouse models. To do this, two studies were conducted. One aimed to determine the 
optimal doses of 25-4 and cisplatin that are required to inhibit tumor growth in an orthotopic 
ovarian cancer model and the second tested 25-4’s ability to synergize with cisplatin. For 
each, A2780 ovarian cancer cells were injected into the peritoneal cavity of nude mice and 
the tumors were allowed to establish. On day 3 of the first study, mice were dosed with 
one of three doses of 25-4 (1, 2.5 or 5 mg/kg given 5 days a week for 4 weeks) or one of 
two doses of cisplatin (2 or 4 mg/kg cisplatin given on days 5, 9, 14, and 21). In a 
 
 
Figure 6: Induction of PARP cleavage by 25-4. Treatment with 25-4 led to PARP 
cleavage in MIAPaCa-2 (pancreatic), SKOV3 and A2780 (ovarian) and HeLa 
(cervical) cancer cell lines. 
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preliminary metabolism study conducted in mice, the plasma concentration of parthenolide 
was 0.112 µM one hour following oral dosing of 4 mg/kg of the drug.124 As the molecular 
weights (248.317 g/mol and 215.21 g/mol, respectively) and potency against TNF-
induced IKKβ-mediated NF-κB activity of parthenolide and 25-4 are comparable and the 
small molecules are expected to exert their effects similar mechanisms of action, we 
choose to treat mice with comparable doses of 25-4 (1, 2.5, and 5 mg/kg). Though PK 
studies were not conducted with 25-4, the goal of this study was just to establish that 25-
4 exhibits anticancer properties in mice and is non-toxic in mice at a therapeutic dose. At 
the end of the study, the mice were sacrificed and the tumor weights determined (Figure 
7). As other  IKKβ inhibitors have shown toxicities in mice, it is important to note that no 
overt toxicity was observed in the mice treated with 25-4 (aside from blocked bowels at 
the highest dose). Additionally, approximately 40% reduction in tumor weights in mice 
 
Figure 7: 25-4 decreases A2780 tumor weight alone and in combination with 
cisplatin in a mouse model of ovarian cancer. Dose-dependent effects on A2780 
ovarian cancer cell growth by 25-4, cisplatin and the combination in an orthotopic 
model of ovarian cancer. P values were calculated only for 2.5 mg/kg 25-4 
compared to vehicle and the combination of 25-4 and cisplatin compared to each 
single treatment. Mouse studies performed by Calvin Tebbe, Adnan R. Munkarah 




treated with 25-4 (5 mg/kg) and 25% reduction of tumor weights in mice treated with 
cisplatin (2 mg/kg) were observed when compared to controls. To determine if 25-4 could 
chemosensitize ovarian tumors to cisplatin, a follow up study in which mice were treated 
with 2.5 mg/kg of 25-4 (5 days a week for 4 weeks) and 2 mg/kg of cisplatin (on days 5, 
9, 14 and 21) was performed. The combination resulted in 60% reduction in tumor weights 
compared to the controls. These studies clearly demonstrate that 25-4 by itself has 
anticancer activity and the ability to chemosensitize ovarian tumors to cisplatin.  
Next, with the help of Dr. Prakash 
Radhakrishnan we performed immunohistochemical 
analysis of the excised tumor tissue (Figure 8). 
Immunohistochemistry revealed that treatment with 
25-4, cisplatin and the combination reduced levels of 
Mcl-1 staining by over 66%.  
On-going projects with 25-4 
To further validate that 25-4 binds to IKKβ and 
p65 to drive cancer cell death, we are conducting a 
series of experiments using click chemistry to 
determine the targets of 25-4. As the small molecule 
is designed to target surface-exposed cysteine 
residues, we first incubated the small molecule at 20 
µM with a panel of cancer cell lines including luciferase A549 cells, which is the cell line 
we used to measure TNF-induced IKKβ-mediated NF-κB-driven transcription activity, 
MBA-MD-231 cells, HeLa cells and SKOV3 cells for 1 h. Cells were harvested and 200 µg 
of whole cell lysate was incubated with TAMRA-azide and additional click reagents for 1 
h. Samples were resolved by SDS-PAGE and fluorescent bands were imaged using the 
Typhoon (Figure 9). At this concentration, time point and Typhoon setting, the luciferase 
 
Figure 8: 25-4 treatment 
reduces Mcl-1 levels in an 
orthotopic model of ovarian 
cancer. Tumor-bearing mice 
were treated with vehicle, 25-
4, cisplatin or the combination 
and immunohistrochemistry 
studies using Mcl-1 antibodies 
were performed on the 
excised tumor tissues. 
Immunohistochemistry 





A549 cells have the most distinct banding pattern but similar bands are seen in the other 
cell lines. 
Moving forward, we characterized the bands (“click signature”) seen in MDA-MB-
231 cells as we had accumulated growth and IKKβ inhibition data in these cells.  First we 
performed a dose-response study with 31-036 and MDA-MD-231 cells (Figure 10, left) 
and saw that 31-036 binding to each of its targets in MDA-MD-231 cells was indeed dose-
dependent. Next, we wanted to see how quickly 31-036 would bind to its targets in cells. 
To test this, we treated MDA-MD-231 cells with 31-036 for 5 min, harvested cells and 
performed click chemistry (Figure 10, right). In MDA-MD-231 cells, 31-036 binding to 
targets occurs within 5 min. Overall, these studies demonstrate that binding of 31-036 to 
target proteins in cells is dose-dependent and rapid.  
To ensure that 25-4 and 31-036, which again is 25-4 with an alkyne handle at the 
R1 position, indeed bind the same targets in cells, a competition assay with the two small 
molecules was performed in MDA-MD-231 cells. MDA-MB-231 cells were incubated with 
 
Figure 9: 25-4 targets proteins in a panel of cancer cell lines. Luciferase A549, 
MDA-MB-231, HeLa and SKOV3 cells were incubated with 31-036 at 20 µM for 1 




31-036 or 25-4 for 1 h or with 25-4 
for 1 h followed by 31-036 for 1 h. 
Cells were harvested and click 
chemistry was performed (Figure 
11). Pre-incubation with 25-4 
decreased the fluorescent signal 
produced by 31-036 following click 
chemistry with 5-TAMRA azide, 
indicating the small molecules 
indeed bind the same targets 
within MDA-MB-231 cells. 
To further study and 
identify all the proteins targeted by 31-036, click chemistry will be performed with 31-036 
and a trifunctional TAMRA-biotin-azide. Cells will be treated with 31-036 and harvested, 
cell lysates will be incubated with TAMRA-biotin-azide and click chemistry will be 
performed. Pulldown of biotin with streptavidin beads will be performed to capture 
TAMRA-biotin-azide in complex with 31-036-targeted proteins. These proteins will then be 
sent out for identification via mass spectrometry (Figure 12 outlines these studies). 
Towards this goal, we have performed click chemistry with both 31-036 and TAMRA-
azide, which has been used in all our previous studies, alongside click chemistry with 31-
036 and the trifunctional TAMRA-biotin-azide (Figure 13). These studies show that click 
 
Figure 10: 25-4 binds to targets in MDA-MB-
231 cells dose-dependently and rapidly. MDA-
MB-231 cells were treated with the indicated 
concentrations of 31-036 for the indicated times, 
harvested and click chemistry with 5-TAMRA 
azide was performed on 200 µg protein. Left) 31-
036 binds dose-dependently to targets within 231 
cells and (Right) binds within 5 min of treatment. 
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chemistry with the TAMRA-biotin-azide has been optimized and the click signature with 
the trifunctional TAMRA-biotin-azide replicates the signature seen with TAMRA-azide 
(Figure 13). 
 Thus far, our studies with 25-4, 31-036 and click chemistry have demonstrated that 
31-036 binding to targets within cells is 
dose-dependent and rapid and that the 
small molecule indeed binds the same 
targets as 25-4. Moving forward, we will use 
a combination of click chemistry and biotin 
pulldowns to determine the targets of 31-
036, including which form(s) of IKKβ is 
targeted by the small molecule. 
Furthermore, we will conduct SAR studies 
to determine which structural changes to 
the scaffold can be made to increase 
specificity towards one target or another to 
characterize the phenotypic consequence of inhibiting each target of 31-036 and to 
explore which effects of the small molecule are through inhibition of IKKβ and which effects 
can be attributed to off-target interactions. 
 
Figure 11: 25-4 and 31-036 bind 
similar targets in MDA-MB-231 cells. 
231 cells were treated with 31-036 or 
25-4 for 1 h or with 25-4 for 1 h followed 
by incubation with 31-036 for 1 h. Click 
chemistry was performed on 200 µg 
protein of resulting lysate. Pre-
incubation with 25-4 reduces the 







Figure 12: Schematic of on-going click chemistry studies. Cancer cells will be 
incubated with 31-036 to allow the small molecule to bind its targets in cell lysates 
(or intact cells). Next, lysate will be incubated with the trifunctional TAMRA-biotin-
azide to label 31-036 with fluorescent rhodamine and biotin. The biotin probe now 
covalently linked to target proteins will be pulled down using streptavidin beads. 
Following pull down, samples will be run on SDS-PAGE and fluorescent bands will 
be imaged using the Typhoon to confirm pull down of trifunctional azide. Bands will 
be excised or tryptic digestion will be performed on protein attached to beads and 
protein targets will be sent for identification via mass spectrometry. 
 
Figure 13: Click chemistry with TAMRA-azide and TAMRA-biotin-azide in cells 
and with pure p65 protein. The click signature for TAMRA-azide and TAMRA-biotin-
azide is similar in cells and with pure protein. Again, this p65 has a 14 amino acid C-




A mechanism-based screen with a focused library of -methylene--butyrolactone 
containing-analogs led to the identification of 25-4 as a potent inhibitor of TNF-induced 
IKKβ-mediated NF-κB-driven transcription activation. SAR studies revealed that 
rigidification of the -methylene--butyrolactone increased the activity of the small 
molecule. Additionally, reduction of the Michael acceptor in 25-4 yielded 25-18, which was 
inactive in all assays it has been tested in. Our studies also showed that 25-4 binds 
covalently to both IKKβ and NF-κB. Furthermore, 25-4 had anticancer activities that are 
comparable to known IKKβ inhibitors and sensitizes SKOV3 ovarian cancer cells to 
treatment with the clinical therapeutic cisplatin. 25-4 inhibited tumor growth by itself and 
in combination with cisplatin in an orthotopic ovarian cancer model to reduce tumor 
burden. Furthermore, treatment with the small molecule resulted in reduced levels of Mcl-
1, which is in line with data seen with other IKKβ and NF-κB inhibitors. Future studies with 
25-4 will be aimed at determining the forms of IKKβ targeted by the small molecule, 
identifying the other targets of 25-4 and building specificity onto the small molecule’s core. 
Importantly, 25-4 is easy to modify and is a suitable starting compound for the extensive 
SAR studies required to identify compounds with improved biological activity, specificity 




Chapter 7: Drug discovery and target validation, discussion of results and future 
directions and closing perspectives 
 
Drug discovery and target validation 
Due to the NF-κB pathway’s implication in cancer, our lab initiated two drug 
discovery projects centered on identifying inhibitors of this pathway. Many lines of 
evidence caused us to pursue the NF-κB pathway as a target, including the mounting 
proof that the pathway plays a key role in K-ras-driven cancers72, 74 and is constitutively 
activated in cancers either by signaling from the tumor microenvironment or genetic 
aberrations.58, 151 Furthermore, tissue specific deletion of pathway members has shown 
much promise in animal-models of disease68, 72-74, 91 and research suggests inhibition of 
this pathway could sensitize cancer cells to clinical chemotherapeutics such as paclitaxel, 
cisplatin and gemcitabine.82, 98, 110, 114, 115  
Small molecule screening typically involves the use of one of two types of 
screening strategies: either target/pathway-based screening (such as a kinase assay) or 
phenotype-based screening, which allows evaluation of a small molecule within cells (such 
as a screen for decreased angiogenesis).152 To begin searching for small molecule 
inhibitors of the NF-κB pathway, we chose a target-based screening strategy in which two 
libraries of small molecules were tested separately in a luciferase assay that monitored 
TNF-induced IKKβ-mediated NF-κB-driven transcription in cells. Though this screen 
allowed us to identify inhibitors that targeted a member of the TNF/IKKβ/NF-κB pathway, 
small molecules identified by assessing a particular target are very likely to interact with 
other proteins in cells and to affect other signaling pathways that may have phenotypic 
consequences in cells.  
To further test a small molecule for specificity towards a particular target, multiple 
experiments can be performed. These include genetic modification of a target protein in 
cells to assess if deletion of the protein reproduces the same phenotype as inhibition of 
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the protein by the small molecule, overexpression or mutation of the protein to drive 
resistance to the small molecule or underexpression of the protein to drive sensitivity to 
the small molecule.152 Additionally, rescue experiments that can outcompete the effects of 
a small molecule can also be performed to assess off-target effects of a small molecule.153  
Furthermore, affinity methods can be used to assess the binding of small 
molecules to targets in cells. With this approach, it is assumed that the protein that binds 
a given small molecule with the highest affinity is the most likely mediator of the biological 
effect of the small molecule in cells. Furthermore, this method usually requires that 1) the 
target protein of a small molecule is abundant in cells or tissues and 2) the small molecule 
is still capable of interacting with its target when attached to resin or biotin, for example, 
in the case of affinity chromatography,154 or a reactive handle, in our case of click 
chemistry. 
Lastly, mechanistic-based evaluation of a small molecule’s activity can be 
performed. For example, inhibition of substrate phosphorylation by a kinase can be used 
to validate inhibition of kinase activity. 
With these principles in mind, a ‘screening cascade’ can be developed to outline 
the biological assays that are required to validate the target of a small molecule. Figures 
1 and 2 give an overview of the assays that were performed to validate IKKβ inhibition by 
13-197 (Figure 1) and 25-4 (Figure 2). In the following discussion, I will touch on each 
experiment conducted with the small molecules and outline how each experiment provides 
evidence that IKKβ is targeted by these small molecules. Furthermore, I will suggest future 
experiments that will be performed to further validate the target of these small molecules 
and investigate possible off-target effects of the compounds. It is important to note that 
this ‘screening cascase’ like most is specific to a target of interest (IKKβ), which limits the 




Validating the targets of small molecule inhibitors and RNAi 
Many of the suggested experiments for determining off-target effects of the novel 
small molecules 13-197 and 25-4 include the use of RNAi or the genetic knockout or 
 
Figure 1: Screening cascade for small molecule 13-197. 13-197 was identified as 
an inhibitor of TNF-induced IKKβ-mediated NF-κB-driven transcription. Follow-up 
studies indicate that the small molecule is an inhibitor of IKKβ. Future studies will be 
aimed at validating IKKβ as a target and assessing off-target effects of 13-197. 
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modification of IKKβ. It is important to remember that although pharmacological inhibition, 
RNA interference and genetic knockout are all complementary methods for assessing the 
phenotype caused by the loss of a protein’s activity, these methods each have their own 
benefits and limitations. For example, small molecules can be costly and time-consuming 
to develop but their rapid induction of activity can prevent compensation by redundant 
pathways in cells. Additionally, they allow the probing of a specific function of a protein 
(kinase activity or a protein-protein or protein-DNA interaction) without abrogating all 
functions of the protein (a scaffolding function in the instance of kinase inhibition). RNAi 
interference and genetic knockout, on the other hand, can be more selective but long-term 
loss of a protein may allow for compensation and will result in the loss of all functions of a 
protein.153 Furthermore, it is key to remember that each method requires its own validation. 
Here I will briefly touch on validation techniques for small molecule inhibitors and RNAi 
approaches. 
In the case of small molecules, SAR studies are required to demonstrate that 
modifying substituents of a core structure leads to a range of potencies against a target of 
interest. Furthermore, an analog with a very similar scaffold but substituent change that 
renders it inactive may need to be developed as a negative control (reduced 25-4 analog 
25-18, for example). Additionally, a small molecule with a very different structure but same 
target and potency for that target can be selected as a positive control. As unrelated core 
structures are expected to have different off-target effects, comparison of the phenotype 
induced by this independent positive control and a novel small molecule under validation 
may give insights into target-independent effects. Lastly, rescue experiments involving the 
expression of a kinase, for example, that is resistant to an inhibitor of interest can be 
performed to study off-target effects. Small molecules should also display dose-
dependency153 as this demonstrates saturatable inhibition of a target. 
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RNAi experiments also require validation and careful consideration. siRNA, for 
example, should be designed after careful analysis of the mRNA sequence being targeted 
to assure targeting of a desired isoform and targeting of a sequence that has little similarity 
to other mRNAs. Again, causality can be confirmed with siRNA. Firstly, a combined pool 
of siRNAs can be used to target a protein of interest. This minimizes off target effects in 
two ways. This allows the use of small concentrations of each siRNA, minimizing the off-
target effect of each but giving efficient reduction in protein production. Furthermore, as 
each siRNA’s off-target effects are sequence, and not necessarily target specific, the use 
of two independent siRNAs to demonstrate the same phenotype upon target repression 
will also establish causality.153 
Additionally, controls such as mock transfection should be performed to control for 
use of transfection reagent. Also, reduction of mRNA should be monitored using RT-PCR 
and loss of protein should be verified by Western blot. Lastly, rescue experiments can also 
be performed with siRNA. Here, the expression of an RNAi-resistant transgene can be 
used to rescue the phenotype.153 
Additionally it is important to keep in mind that each method may result in a 
different phenotype, making it difficult to draw exact correlations between pharmacological 
inhibition and genetic inhibition.153 For example, if IKKβ’s role as a member of the IKK 
complex (and not just as a catalytic subunit of the complex) is key for the protein’s activity 
in some biological process, inhibition of the protein using a pharmacological agent such 
as 13-197 or 25-4 may not affect its function in this particular pathway. However, loss of 
IKKβ through RNAi or genetic knockout may induce a phenotype dependent on the loss 
of IKKβ function as a scaffold. To test if IKKβ plays a scaffolding role, catalytically inactive 
IKKβ can be expressed in RNAi-targeted to cells to rescue the phenotype induced by loss 
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of IKKβ protein but not enzymatic activity. This phenotype should mirror that of 
pharmacological inhibition of the kinase. 
 
 
Figure 2: Screening cascade for small molecule 25-4. Like 13-197, 25-4 was 
identified as an inhibitor of TNF-induced IKKβ-mediated NF-κB-driven transcription. 
Follow-up studies indicate that the small molecule targets IKKβ and p65. Future 
studies will be aimed at validating IKKβ and p65 as targets and will identify additional 
cellular targets of 25-4 using click chemistry. 
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Discussion of results presented in this dissertation 
In the previous two chapters, I have introduced two novel small molecule inhibitors 
of IKKβ, 13-197 (Chapter 5) and 25-4 (Chapter 6), and have shown their promise as 
potential therapeutics for the treatment of cancer as single agents or in combination with 
clinical therapeutics (Figures 5.1, 5.2, 5.9, 5.10, 5.11, 6.4. 6.5, 6.6, 6.7 and 6.8 on pgs 42, 
43, 50, 51, 53, 62, 63, 64, 65 and 66, respectively) In this final chapter, I will further expand 
upon the results presented for each small molecule and discuss how the effects of 13-197 
and 25-4 correlate with the effects of genetic or pharmacological inhibition of the NF-κB 
pathway by others. Furthermore, I will touch upon the limitations of the work presented in 
this dissertation and discuss future experiments that could be performed to strengthen 
and further support our conclusions. I will discuss the implications of the work presented 
here and the newly published crystal structure of phosphorylated and non-phosphorylated 
human IKKβ protomers and conclude with my perspectives regarding the development of 
small molecule inhibitors of IKKβ. 
Hit identification of and SAR studies with 13-197 and 25-4 
Small molecules 13-197 and 25-4 contain a quinoxaline core and a lactone motif, 
respectively (Figure 3.7 pg 35). These two structures can be considered “privileged 
structures” as the quinoxaline core serves as a scaffold in a wide variety of molecules with 
biological activity and molecules containing -methylene--butyrolactones have been 
used for the treatment of a variety of indications.129, 131 As such, chemists in the laboratory 
designed two small molecule libraries: one containing analogs featuring each structure. 
My work with small molecule 13-197, which had been identified as an inhibitor of 
TNF-induced IKKβ-mediated NF-κB-driven transcription by Dr. Vashti C. Bryant in a 
large primary screen (data not shown), began with studies focused on determining 
structure activity relationships for 13-197 and related quinoxaline analogs (Figure 5.3 pg 
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45). To perform this study, a focused subset of quinoxaline urea analogs was tested again 
for activity specifically against TNF-induced IKKβ-mediated NF-κB-driven transcription 
of firefly luciferase in our lung adenocarcinoma cell line genetically engineered to express 
firefly luciferase from a promoter containing a kB element. This study was performed to 
assess inhibition of NF-κB activity for two reasons. The first of these reasons is that 
inhibition of TNF-induced IKKβ-mediated NF-κB-driven transcription of firefly luciferase 
would report on small molecule activity towards the NF-κB pathway only. Assuming off-
target effects of 13-197 and 25-4 did not induce alterations in transcription or translation 
of firefly luciferase or the small molecules did not target firefly luciferase itself, the effects 
of decreased luciferase activity could be attributed solely to modulation of the NF-κB 
pathway. Secondly, inhibition of NF-κB-driven firefly luciferase transcription at varying 
degree of potencies by multiple small molecules with a similar core but differing 
substituents establishes causality,153 further confirming that inhibition of the NF-κB 
pathway by 13-197 (and 25-4, for that matter) was indeed due to inhibition of an NF-κB 
pathway member. For studies with 25-4 (Figure 6.1 pg 58), the luciferase assay was used 
first to identify 25-4 as a small molecule inhibitor of an NF-κB pathway member (as 13-
197 had been identified by Dr. Vashti C. Bryant). Follow-up SAR studies using the 
luciferase assay gave insights into the key structural features of the small molecule and 
its analogs (Figure 6.2 pg 59). 
The SAR studies identified substituents key for the activity of 13-197 and 25-4. For 
example, the presence of a five- or six-membered ring at the R1 positions of 13-197 was 
key for its activity (Figure 5.3 pg 45), suggesting this region of the small molecule makes 
key contacts with IKKβ. Furthermore, a bromo- group at the R2 position of 13-197 was 
also key for the molecule’s activity again suggesting this group was key for proper binding 
to the target protein. These observations are being tested by Jacob Contreras who is 
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developing 13-197 analogs with modifications at the R1 positions of the small molecule. 
Testing of these analogs will yield further insight into the interactions made by these 
groups. 
In the SAR studies conducted with 25-4 (Figures 6.1 and 6.2 pgs 58 and 59), 
reduction of the Michael acceptor resulted in loss of activity of the small molecule, 
indicating loss of activity against NF-κB pathway members. This observation is consistent 
with those for the reduction of the Michael acceptor of the natural product parthenolide. 
Upon reduction of its Michael acceptor, parthenolide loses its activity towards IKKβ.122 
Furthermore, these studies demonstrated that rigidification of the Michael acceptor was 
key for 25-4 activity. This phenomenon suggests to us that rigidification of the small 
molecule likely reduces interactions with off-target proteins by decreasing the flexibility of 
the Michael acceptor and thus non-specific interactions with surface exposed cysteine 
residues. This study can be expanded through generation and testing of additional 
analogs that further explore the requirement for the Michael acceptor and its rigidification. 
In luciferase screens with these small molecules, the known IKKβ inhibitor 
parthenolide was used as a positive control. In studies with 13-197, parthenolide was 
chosen as a control simply to demonstrate inhibition of NF-κB pathway activation by a 
known IKKβ inhibitor. 
Parthenolide’s use in the screen with 25-4 was two-fold. In this screen, it was again 
used a positive control but it was also chosen because it shares the -methylene--
butyrolactone present in 25-4. Parthenolide’s use in this screen thus gave us information 
regarding the level of pathway inhibition that could possibly be expected upon treatment 
with 25-4 and its analogs. Furthermore, the use of reduced-parthenolide allowed us to 
demonstrate the requirement of the Michael acceptor for parthenolide’s activity in the 
screen and to establish a rationale for 25-18’s (reduced 25-4’s) lack of activity. 25-4 
showed inhibition of NF-κB pathway activity that was comparable to inhibition by 
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parthenolide (75% vs 100%) (Figure 6.2 pg 59). Additionally, the IC50 value for 
parthenolide in our TNF-induced IKKβ-mediated NF-κB-driven transcription assay is 
4.7±1.5 µM,127 which was in line with the IC50 value of 25-4 in this cell line. 
Parthenolide showed approximately 55% inhibition of TNF-induced, IKKβ-
mediated, NF-κB-driven transcription in the screens conducted with 13-197 (Figure 5.3 pg 
45) while it showed nearly complete inhibition of NF-κB activity in screens with 25-4 and 
its analogs (Figure 6.2 pg 59). The parthenolide used in the studies with 25-4 was made 
fresh and specifically for testing alongside 25-4. Whenever I conducted the assays with 
13-197, the parthenolide stock solution used was not made fresh but had instead been 
made by Dr. Vashti C. Bryant during her studies. Issues regarding the stability of this 
natural product in DMSO or over the course of many freeze-thaw cycles could have 
contributed to this discrepancy. 
Target Validation: 13-197 
The next experiments performed with 13-197 and 25-4 were directed at 
determining the molecular targets of the small molecules. For 13-197, the small molecule’s 
activity towards a panel of kinases was determined in kinase assays carried out by 
Reaction Biology Corp. (Figure 5.4 pg 46). An initial screen was conducted in which 13-
197 was tested at 1 µM against a panel of kinases. The resulting hits from these single 
concentration assays were then incubated with 13-197 at 10 concentrations starting at 
100 µM compound with 9 1:3 serial dilutions to generate IC50 values. Six kinases were 
identified as hits of 13-197 in the screen. These included TRKA, IKKβ, EPHA6, Nek3, 
MAP4K4 and STK25. The IC50s for TRKA, IKKβ, EPHA6 and Nek3 were in the low µM 
range while those for MAP4K4 and STK25 were in the mid µM range. Due to their lower 
IC50 values, we focused our attention on the kinases TRKA, IKKβ, EPHA6 and Nek3. 
MAP4K4, however, is known to be activated by TNF.155 TRKA plays a role in the 
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development and maturation of the central and peripheral nervous systems.156 EPHA6 is 
expressed mainly in the brain.157 Nek3 plays a role in the motility of breast cancer cells.158 
Due to the physiological roles of these kinases, we chose to move forward by 
characterizing the effects of 13-197 on IKKβ as it is the main kinase in the NF-κB pathway. 
Nevertheless, we are mindful of the fact that inhibition of Nek3 and MAP4K4 may also 
play a role in the phenotypes induced by 13-197 treatment. 
The human kinome contains 518 kinases159 while the panel used in the Reaction 
Biology Corp. screen only contained 318 kinases. Though the implications of this study 
are limited by the size of the panel used, the results establish 13-197 as an inhibitor of 
IKKβ and confirm that inhibition of NF-κB-driven transcription by 13-197 in the luciferase 
assay was indeed likely due to targeting of the NF-κB pathway. To further confirm inhibition 
of IKKβ by 13-197, Dr. Vashti C. Bryant, performed and in vitro ELISA assay with IKKβ 
and 13-197. In this assay, 13-197 inhibited IKKβ with an IC50 of approximately 14 µM, 
again confirming these results. These experiments are in line with experiments confirming 
inhibition of IKKβ by the commercially available IKKβ inhibitors TPCA-1118 and BMS-
345541119 though our kinase screen was much more expansive (318 kinases vs 10 and 
15 kinases, respectively). Though off-target effects through inhibition of TRKA, EPHA6 
and Nek3 have not yet been assessed, we expect those through inhibition of MAP4K4 
and STK25 to be minimized by the use of sub-IC50 concentrations of 13-197 for these 
proteins. Through SAR studies we may be able to identify analogs of 13-197 that have 
increased specificity for IKKβ. The use of these small molecules, other known IKKβ 
inhibitors and RNA silencing of IKKβ alongside 13-197 in phenotypic assays (cell 
proliferation, death, angiogenesis) in which 13-197 is expected to display activity may give 





Target Validation: 25-4 
As the -methylene--butyrolactone in 25-4 is also present in parthenolide, which 
has been shown to target C179 of IKKβ and C38 of NF-κB subunit p65122, 130 we first sought 
to validate binding of 25-4 to these targets. To do this, we used click chemistry (Figure 
6.3A pg 60), which is emerging as a powerful strategy for identifying the targets of covalent 
small molecules.148, 160 For these experiments, an alkyne-tagged version of 25-4 (31-036) 
was synthesized by Dr. Sandeep Rana in the lab. Following incubation with live cells, cell 
lysates or pure protein the alkyne tag on this small molecule, which is now covalently 
bound to target, reacts with the azide tag of TAMRA-azide following incubation with TCEP, 
TBTA and CuSO4×5H20 to generate a triazole product covalently linked to 31-036-targeted 
proteins. Tagged protein is then precipitated with methanol to remove excess, unbound 
TAMRA-azide and precipitated protein is resuspended in sample buffer, boiled and 
resolved on SDS-PAGE. Importantly, the intrinsic fluorescent properties of the flurophore 
allows for the visualization of targets via in-gel fluorescence. Click chemistry with 25-4 
analog 31-036 confirmed binding of the small molecule to both IKKβ and p65. As these 
results were in line with the activity of 25-4 in the luciferase assay, which reports 
specifically on the inhibition of NF-κB pathway members, we moved forward to further 
validate 25-4 as an inhibitor of IKKβ.  
The pure p65 used for this experiment had a 14 amino acid truncation at the C-
terminus, partially explaining its molecular weight of less than 65 kDa (Figure 6.3A pg 60). 
In our experiments, this commercially available p65 consistently runs at the shown 
molecular weight and reacts with anti-p65 antibody if the gel is transferred to a membrane 
and blotted for p65 following visualization of in-gel fluorescence (data not shown). For this 
experiment, we were unfortunately unable to generate a loading control. Following 
detection of in-gel fluorescence, the gel was stained with Bio-safe Coomassie. 
Unfortunately, the amount of protein loaded on the gel appears to be below the limit of 
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detection for the reagent. In subsequent experiments, equal loading may be confirmed by 
silver staining. 
Though binding to IKKβ and NF-κB specifically was assessed in this experiment 
(Figure 6.3A pg 60), 25-4 and 31-036 are covalent small molecules that react with surface 
exposed cysteine residues in cells. Due to this mechanism of action, these small 
molecules likely bind targets besides IKKβ and p65. However, the point of this experiment 
was only to validate that 25-4 has targets within the NF-κB pathway that overlap with 
parthenolide’s targets as 25-4 contains the same Michael acceptor present in the NF-κB 
pathway inhibitor parthenolide and exhibited activity against NF-κB pathway activation in 
the luciferase screen. 
Distinguishing IKKβ/NF-κB-dependent effects from IKKβ/NF-κB-independent effects: 13-
197 
 
 Given that 13-197 has been shown to target kinases besides IKKβ (TRKA, EPHA6, 
Nek3, MAP4K4 and STK25), future studies will be aimed at determining the consequences 
of targeting these proteins alone and in combination with IKKβ. Experiments with siRNA 
and small molecule inhibitors will be conducted to determine how loss of these proteins' 
activities and loss of IKKβ activity affect cellular function. For example, MiaPaCa-2 cells 
will be transfected with siRNA against each individual target to assess the consequence 
of inhibiting each individual target to provide insight into IKKβ-dependent and possible 
IKKβ-independent effects of 13-197. Additionally, siRNA against all 6 targets and siRNA 
against the 5 non-IKKβ targets will be pooled to compare the effects of silencing all targets 
of 13-197 and all non-IKKβ targets of 13-197. Furthermore, treatment with 13-197 will be 
compared to treatment with the pool of siRNA against all 6 of the small molecule's known 
targets and the 5 non-IKKβ targets of 13-197. If inhibition of IKKβ by 13-197 is indeed key 
for the small molecule's anticancer activity, transfection with the pooled siRNA of non-
IKKβ targets will not yield the anticancer effects associated with 13-197 treatment 
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(decreased cell viability, reduced levels of anti-apoptotic proteins). However transfection 
with siRNA against IKKβ alone or the pool of all 6 siRNAs including anti-IKKβ siRNA will 
recapitulate treatment with 13-197 if IKKβ inhibition is key for the molecule's activity. 
Furthermore, addition of an IKKβ inhibitor such as ML120B or TPCA-1 to cells transfected 
with the pool of non-IKKβ siRNAs should mimic all IKKβ-dependent effects of 13-197 
treatment. Additionally, treatment with 13-197, ML120B and TPCA-1 will be compared to 
treatment with siRNA against IKKβ alone to validate that treatment with the small 
molecules replicates silencing of IKKβ. If the effects of 13-197 do not appear to be due 
solely to inhibition of IKKβ by 13-197 (for example, if treatment with 13-197 does not mimic 
treatment with IKKβ siRNA alone but more closely mimics treatment with the pool of siRNA 
against all 6 targets), siRNA against IKKβ will be tested in MiaPaCa-2 cells in combination 
with siRNA against the other targets one by one to test for sensitization to treatment with 
IKKβ siRNA. This may answer questions regarding the importance of targeting other 
pathway members upstream of IKKβ (MAP4K4) or those with known roles in cancer 
progression (Nek3). 
Distinguishing IKKβ/NF-κB-dependent effects from IKKβ/NF-κB-independent effects: 25-
4 
 
Given that most of the targets of 25-4 are still unknown, assessing the IKKβ/NF-
κB-dependent effects of 25-4 will be a challenging task. Experiments designed to identify 
the targets of 25-4 are currently underway. Briefly, cells will be treated with 25-4 analog 
31-036, harvested and lysed. Next click chemistry will be performed as previously 
described with lysate and TAMRA-biotin-azide to covalently attach biotin to the 31-036 
covalently linked to target proteins. Lysate will then be incubated with streptavidin beads 
to pull down the targets of 31-036. Mass spectrometry will be performed to identify these 
targets. A benefit of this methodology is that all proteins (enzymes, transcription factors, 
etc.) targeted by 31-036 can be identified using a single technique.  
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Once the targets of 25-4 analog 31-036 are known, studies assessing the 
IKKβ/NF-κB-independent effects of 25-4 can be conducted. Analysis of the known 
consequences of inhibiting 31-036 or 25-4 targets may provide insight into any IKKβ/NF-
κB-independent effects on viability and apoptosis. Furthermore, click chemistry SAR 
studies with 31-036 analogs will be conducted to identify analogs with fewer targets. 
Treatment of cells with analogs that all target IKKβ and p65 but distinct non-IKKβ and NF-
κB targets of 25-4 analog 31-036 may give information regarding other targets that are 
essential for the anticancer properties of the parent compound 25-4. Once the targets of 
31-036 are known and analogs targeting IKKβ, NF-κB and distinct subsets of 31-036’s 
other targets have been identified, we may perform siRNA studies similar to those 
proposed for 13-197 with 31-036 analogs with only a few (~5 or fewer) targets. In addition 
to transfecting cells with each siRNA individually, we will also transfect cells with pooled 
siRNA against all the known targets of an analog. In these studies, we will measure 
decreased viability, induction of apoptosis, inhibition of IκB phosphorylation and p65 
nuclear translocation (to monitor IKKβ/NF-κB pathway inactivation) and the downstream 
consequences of inhibiting the non-IKKβ and NF-κB targets of the analogs. Comparison 
of the degree of decreased viability and induction of apoptosis in cells treated with different 
siRNAs against non-IKKβ and NF-κB targets may reveal that inhibition of other pathways 
contributes to the decreased cell viability and induction of apoptosis seen by 25-4.  
Lastly, the described studies using C179A IKKβ and/or C38S p65 expressing cells 
will give further insight regarding the IKKβ and p65-independent effects of 25-4 (and 25-4 
analogs). Cells expressing C179A IKKβ will be resistant to IKKβ inhibition by 25-4 while 
C38S expressing cells will be resistant to inhibition of p65 DNA binding by 25-4. Cells 
expressing both C179A IKKβ and C38S p65 will be resistant to inhibition of both IKKβ and 
p65 by 25-4. Overall, use of the C179A or C38S cell lines will elucidate the importance of 
targeting IKKβ or p65 while the use of cells expressing both C179A IKKβ and C38S p65 
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will give insight into the IKKβ and NF-κB-independent effects of 25-4. For example, if 25-
4 treatment of C179A IKKβ/C38S p65 expressing cells still results in decreased cell 
viability or induction of apoptosis, we can conclude that 25-4's anticancer effects may be 
partially due to inhibition of other targets. Identification of analogs that still target IKKβ and 
p65 but exhibit no anticancer activities in C179A IKKβ/C38S p65 expressing cells may 
identify analogs that are selective for the NF-κB pathway.  
Though 25-4 has many targets and IKKβ and NF-κB-independent effects likely 
contribute to the anticancer effects of the small molecule, 25-4 is a small molecule that 
binds IKKβ and NF-κB, displays anticancer effects and is highly amenable to modification. 
As such, we intend to use the small molecule as a scaffold onto which we can, through 
functionalization, build specificity onto this molecule to design a more specific, yet still non-
toxic, inhibitor of IKKβ and p65. The studies outlined in this dissertation provide preliminary 
evidence that IKKβ can be targeted with small molecules without inducing toxicity but 
future studies by our lab will be required to develop small molecule 25-4 as a specific 
inhibitor of the NF-κB pathway. 
Mechanism of action: 13-197 
As our luciferase assay reports on TNF-induced IKKβ activation, we tested the 
ability of 13-197 to inhibit the phosphorylation of IκB, the downstream target of IKKβ, 
following cellular stimulation with TNF (Figure 5.5 pg 47). For this studies, cells were 
pretreated with 13-197 for 2 hours prior to stimulation with TNF for increasing times. In 
the first of these studies, HEK293 cells were pretreated with DMSO or 13-197 for 2 hours 
and then stimulated with TNF for 0, 5, 10, 15, 20, 30, 45, 60, 75, 90 and 120 minutes 
and levels of phosphorylated and total IκB were monitored. In this experiment, 13-197 
did not markedly decrease phosphorylation of IKKβ’s substrate at early time points but 
instead decreased phosphorylation of IκB following the degradation and resynthesis of 
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IκB in response to signaling through the NF-κB pathway (this phenomenon of IκB 
degradation and resynthesis is not unique to our studies but rather appears to be a general 
feedback mechanism for regulating the activation of the pathway161). To us, this 
experiment suggested that 13-197 was inhibiting a form of IKKβ that persists at later time 
points but is not present immediately following activation of the kinase.  
It is well-accepted that IKKβ is phosphorylated upon its T loop serine residues to 
drive its activation. Once activated, the kinase autophosphorylates a stretch of its own C-
terminal serine residues, which serves to dampen the kinase’s activity and provides 
docking sites for phosphates that can dephosphorylate the T loop serine residues to return 
the kinase to a resting state.2, 125 Using this model (Figure 3.6 pg 32) for the progressive 
phosphorylation of IKKβ, we hypothesized that 13-197 selectively targets IKKβ with its T 
loop phosphorylated but allows the activation of unphosphorylated IKKβ to yield brief 
signaling through the pathway. 
 As ML120B pre-treatment had already been shown to inhibit the early activation of 
IKKβ in response to stimulation with TNF,117 we decided to compare inhibition of TNF-
induced IKKβ activation by 13-197 and the IKKβ inhibitor TPCA-1 (Figure 5.6 pg 48). 
HEK293 cells were pretreated with DMSO, TPCA-1 or 13-197 and then stimulated with 
TNF for 5 or 10 minutes. Like ML120B, pre-treatment with TPCA-1 completely blocked 
phosphorylation of IκB upon cellular stimulation with TNF. 13-197, on the other hand, 
allowed marked phosphorylation of IκB within 10 minutes of stimulation, again 
suggesting the small molecule allows the activation of IKKβ. 
Both of these studies analyzed downstream effects of the activation of IKKβ in 
response to stimulation of the kinase with a known IKKβ activator and are nearly identical 
to experiments establishing ML120B as an inhibitor of IKKβ and similar to experiments 
establishing TPCA-1 as an IKKβ inhibitor.117, 118 However, these experiments have not 
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addressed the possibility that 13-197 targets a kinase upstream of IKKβ to block 
phosphorylation of IκB or decreases the levels of IKKβ by inhibition of its transcription, 
for example. Immunoblotting for phosphorylated (and thus activated) IKKβ and total IKKβ 
alongside blotting for phosphorylated and total IκB would establish that IKKβ was indeed 
activated (high IKKβ phosphorylation) and inhibited (low IκB phosphorylation). However, 
these experiments were performed prior to our lab’s identification of suitable antibodies 
for detecting total and phosphorylated IKKβ. In future repeats of these experiments, 
lysates will also be probed for phosphorylated and total IKKβ. 
Importantly, the mechanism of action established in these studies with 13-197 is 
in contrast to what is seen with ML120B and TPCA-1, which have both shown toxicities in 
animal models.74, 162 As partial or transient inhibition of IKKβ has been hypothesized to be 
less toxic than complete inhibition of IKKβ,163 we continued our studies with this small 
molecule by testing it for efficacy against cancer cell lines (continued in next section 
discussing 13-197). 
Mechanism of action: 25-4 
 As mentioned already, parthenolide covalently interacts with C179 of IKKβ and 
C38 of p65.122, 130 We expect 25-4 to bind to these proteins through covalent interactions 
with the same residues through the -methylene--butyrolactone present in its structure. 
We have not tested this mechanism of action directly, though follow-up studies with 25-4 
and its reduced analog 25-18 indicate that covalent interaction between the Michael 
acceptor and exposed cysteine residues of an NF-κB pathway member are indeed key for 
activity (Figures 6.1 and 6.2 pgs 58 and 59). Our first cell-based studies were used to 
validate the SAR seen with the butyrolactone analogs in the luciferase assay. Due to NF-
κB’s known roles in disease progression, anti-apoptosis and chemoresistance in breast 
cancer76-79 we opted to study the pathway in breast cancer cells as well as pancreatic 
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cancer cells. Basal activation of the NF-κB pathway is known to be high in MDA-MB-231 
cells78 and is confirmed by the high basal levels of phosphorylated IκB in the MDA-MB-
231 cells used in these studies (Figure 6.3B pg 60). The high expression of IKKβ in these 
cells has been linked to sensitivity to the IKKβ inhibitor sulindac, which drives apoptosis 
in MDA-MB-231 cells.78 
Reduced phosphorylation of IκB was observed in MDA-MB-231 cells treated with 
25-4 (Figure 6.3B pg 60), which is expected as 25-4 was active in the luciferase assay. 
Furthermore, treatment with the reduced version of 25-4 (25-18) resulted in no inhibition 
of IκB activity, which again aligns with our results from the luciferase assay. As reduction 
of the -methylene--butyrolactone of parthenolide resulted in loss of binding to IKKβ122 
and activity towards NF-κB-driven transcription in our luciferase assay, our observation 
that the Michael acceptor of 25-4 is key for activity is substantiated by work conducted 
with similar molecules.  
Treatment with small molecule 28-090 (25-4 in which the Michael acceptor has 
been made less rigid), resulted in partial decrease in IκB phosphorylation but the small 
molecule was less active than 25-4 (Figure 6.3B pg 60), suggesting rigidification of the 
Michael acceptor is key for activity towards IKKβ. This observation is further supported by 
the activity of cyclic 28-097C towards phosphorylation of IκB but lack of activity by its 
acyclic analog 28-097A. Once more, the results of this experiment are in line with the 
results of the luciferase assay (Figure 6.1 pg 58). Additionally, the molecules tested for 
inhibition of IκB phosphorylation were able to do so at concentrations similar to those 
used in the luciferase assay, demonstrating that the small molecules inhibit IKKβ activity 
in cells with the same rank potency they displayed in the previous assay designed to test 
their activity against the NF-κB pathway.  
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Again, we hypothesize that rigidification of the Michael acceptor decreases 
promiscuity of the cyclic small molecules by decreasing the number of interactions the 
Michael acceptor may make with surface-exposed cysteine residues. Due to their inherent 
flexibility, the acyclic 28-090 and 28-097A are able to interact with additional cysteine 
residues in cells, thereby decreasing their activity towards NF-κB pathway members and 
thus decreasing their activity towards IKKβ and NF-κB and reduction of IκB 
phosphorylation and NF-κB-driven transcription. To further explore the importance of the 
Michael acceptor or rigidification of the Michael acceptor, additional analogs with 
modifications similar to those seen between 25-4 and 25-18 (reduction of Michael 
acceptor), 25-4 and 28-090 (loss of rigidity of Michael acceptor), and 28-097C and 28-
097A (loss of rigidity of Michael acceptor) could be synthesized to further confirm this 
phenomenon. 
To further test that 25-4 binds to C179 of IKKβ, cells expressing mutant C179A 
IKKβ (which cannot covalently interact with the -methylene--butyrolactone122) could be 
treated with 25-4. Treatment of these cells with 25-4 should have no effect on IκB 
phosphorylation if inhibition of IκB phosphorylation in these cells is due to inhibition of 
IKKβ through covalent interaction with C179. However, if 25-4 is affecting a different 
residue, an upstream kinase or total levels of IKKβ, inhibition of IκB phosphorylation will 
still be seen. Validation that C179A IKKβ still phosphorylates IκB will be performed. 
Furthermore, experiments similar to those conducted with 13-197 (pre-treatment with 
DMSO or compound followed by stimulation with TNF for increasing times) may be 
conducted to test if 25-4 binds resting IKKβ or selectively targets a phosphorylated form 
of IKKβ. Again, in these experiments, levels of phosphorylated and total IKKβ and 
phosphorylated and total IκB will be assessed to monitor if the kinase is active at early 
time points and inhibited at late time points. However, as 25-4 also targets p65, it is 
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important to remember that resynthesis of IκB may not occur in cells pretreated with 25-
4 as the protein’s re-expression is driven by NF-κB translocation to the nucleus and 
induction of transcription. In such an event, the experiment will be modified such that 
treatment with 25-4, which binds it targets within 5 minutes (see 5 minute incubation with 
31-036 followed by click chemistry, Figure 6.10 pg 68), will occur after stimulation with 
TNF to drive phosphorylation and activation of IKKβ. 
To test if inhibiting IKKβ gives the same effect as inhibiting both IKKβ and p65, 
cells expressing C38S p65 (which cannot covalently interact with a Michael acceptor but 
can still bind κB sites in DNA130) could be treated with 25-4 alongside wild-type cells. In 
this experiment, 25-4 will inhibit both IKKβ and p65 in wild-type cells but only IKKβ in C38S 
p65 cells. Prior to conducting this experiment alongside wild-type cells, p65 binding to 
DNA as well as levels of total and phosphorylated IKKβ and IκB will be monitored in 
untreated, C38S p65 cells to ensure the pathway is functioning properly in the mutant 
cells. Upon treatment, levels of total and phosphorylated IKKβ and IκB will be monitored 
and compared to levels in untreated cells to probe for inhibition of IKKβ as assessed by 
decreased IκB phosphorylation. Additionally, p65 binding to DNA or translocation to the 
nucleus can be monitored to assess pathway inhibition. With C38S p65 cells, pre-
treatment with drug followed by TNF stimulation could be performed, as p65 should still 
be functional in these cells and will still drive IκB re-expression to give a readout 
(decreased IκB phosphorylation) for IKKβ inhibition. 
Overall, despite the limitations of this experiment, this mechanism-based study 
verified that 25-4 inhibited the phosphorylation of IKKβ’s substrate IκB in MDA-MB-231 





Mechanism-based studies in cancer cells: 13-197 
As previously mentioned, we next sought to test the ability of 13-197 to inhibit the 
phosphorylation of IκB in cancer cells. As NF-κB pathway activation is implicated in 
pancreatic cancer72, 73, 90 and IKKβ activation is implicated in the development of K-ras-
driven pancreatic cancers72, 93 we chose to study activation of IKKβ and the consequences 
of its inhibition in pancreatic cancer cells.  
First, we tested a panel of cancer cell lines for phosphorylated IKKβ and found that 
IKKβ was indeed activated in these cells (Figure 5.7 pg 49). Next, we tested the ability of 
13-197 to inhibit IκB phosphorylation in pancreatic cancer cells (Figures 5.8 and 5.9A 
pgs 49 and 50). Treatment with 13-197 decreased IκB phosphorylation in a panel of 
pancreatic cancer cells lines (AsPC-1, Capan-2, Hs766T, MIAPaCa-2 and SUIT-2) and 
reduced phosphorylation of IκB in MIAPaCa-2 pancreatic cancer cells in a dose- and 
time-dependent manner. As NF-κB regulates a number of genes that play a role in the 
proliferation of cancer cells and genetic ablation or pharmacological inhibition of IKKβ has 
been shown to reduce cancer cell proliferation,66, 74 we next determined if inhibition of the 
pathway would result in decreased viability of cells (Figure 5.9B and C pg 50). Indeed, 
treatment with 13-197 decreased the viability of pancreatic cancer cells with low µM 
potency. Furthermore, the IC50 of 13-197 in this panel of cancer cell lines is within the 
same range of potency of other small molecule inhibitors of IKKβ. 
To further study the effects of 13-197 on cell proliferation, a collaborator, Dr. 
Prakash Radhakrishnan, analyzed the effects of 13-197 on the cell cycle and saw that 
treatment with the small molecule induces apoptosis, blocks cell cycle progression and 
reduces levels of PCNA.128 These effects are in line with those seen with other 
pharmacological inhibitors of IKKβ.74, 164, 165 As Bcl-xL, Mcl-1, XIAP and survivin are under 
the transcriptional control of NF-κB,21, 23-25 I treated MIAPaCa-2 cells with 13-197 and 
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probed lysates for expression of these anti-apoptotic proteins (Figure 5.10 pg 51). 
Treatment with the small molecule resulted in decreased levels of these proteins, 
providing a biological rationale for the results of Dr. Radhakrishnan’s studies. Furthermore, 
these results are in line with those seen in other models of pharmacological IKKβ inhibition 
or NF-κB pathway inhibition with the IκB superrepressor.166-168 
Mechanism-based studies in cancer cells: 25-4 
As the activation of the NF-κB pathway is implicated in the progression of not just 
pancreatic cancer but many others, including lung,74, 75 breast,58, 76-79 ovarian, 80-82 and 
cervical107, 110 cancers and has been shown to play a role in inflammation, transformation, 
proliferation, angiogenesis, invasion, metastasis, chemoresistance and radioresistance,83 
we expanded the cells lines in our studies with 25-4 to encompass a diverse panel of 
cancer cell lines. 
As mentioned previously, 25-4 showed activity against phosphorylation of IκB in 
MDA-MD-231 breast cancer cells (Figure 6.3B pg 60). Additionally, 25-4 displayed dose- 
and time-dependent activity in MIAPaCa-2 pancreatic cancer cells (Figure 6.3C pg 60), 
which were established to have basal phosphorylation of IKKβ (Figure 5.7 pg 49) and 
basal phosphorylation of IκB (Figures 5.9A and 6.3C pgs 50 and 60) suggesting that the 
NF-κB pathway is active in these cells. Furthermore, the IC50 for 25-4, as measured by 
cell viability assay, in these two cell lines was in the low µM range, which is again, in line 
with the IC50s for the known IKKβ inhibitors TPCA-1 and Bayer Compound VIII (Chapter 6, 
Table 1 pg 62). 25-18 was again inactive in these cell lines, supporting the argument that 
reduction of the Michael acceptor abolishes the small molecule’s activity. Furthermore, the 
reported IC50 values for parthenolide against acute myelogenous leukemia, lung, breast 
and pancreatic cancer cell lines is typically within the 0.5 to 17.5 µM range,169-172 which is 
again in line with the potency of 25-4 in our studies. 
95 
 
 As IKKβ and the NF-κB pathway are known to play a role in many tumorigenic 
properties of cancer cells, we next assessed the ability of 25-4 to inhibit colony formation 
(Figure 6.5A and B pg 63) and induce apoptosis in cancer cells (Figures 6.5C and 6.6 pgs 
63 and 64). The colony formation assay was conducted as this assay monitors the 
reproductive viability of cancer cells after treatment with drug.173 Overexpression of NF-
κB is associated with increased colony formation by cervical cancer cells while silencing 
of the protein results in decreased colony formation.107 To test if inhibition of IKKβ by 25-
4 could prevent colony formation of cervical cancer cells, Tian Zhou performed colony 
formation assays in HeLa cells treated with DMSO, 25-4 and the reduced version of 25-4 
(25-18). In the assay, cells were seeded at low density (500-1000 cells/well) in 6-well 
plates, given 24 hours to attach to the plate and treated with drug for 48 hours. The media 
above the cells was replaced and the cells were cultured for 7 additional days before 
fixation with methanol, staining and quantification of colonies. This method is similar to 
that used by others104, 107, 174 to assess clonogenecity of cells with NF-κB activation. 
Treatment with 25-4 dose-dependently inhibited colony formation while treatment with a 
dose of 25-18 equivalent to the highest dose of 25-4 had no activity.  
For this study, additional IKKβ inhibitors such as parthenolide, ML120B, TPCA-1 
or Bayer Compound VIII could have been tested to show similar effects by known IKKβ 
inhibitors. Furthermore, knockdown of IKKβ or p65 could also validate these results by 
showing effects similar to those of 25-4 treatment. Additionally, cells overexpressing IKKβ 
and p65 or cells expressing C179A IKKβ and C38S p65 could have been treated alongside 
wild-type cells to show resistance to treatment or rescue of the phenotype by cells that are 
expected to be resistant to 25-4 inhibition of IKKβ and p65. 
NF-κB activation and IKKβ expression are associated with poor survival of ovarian 
cancer patients and chemoresistance of ovarian cancer cells.80, 81, 99 As inhibition of IKKβ 
has been shown to decrease viability of ovarian cancer cells99 and NF-κB pathway 
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inhibition has been associated with increased ovarian cancer cell sensitivity to the 
chemotherapeutic cisplatin,110 which is commonly used in the treatment of ovarian 
cancer,150 we next tested the ability of 25-4 to decrease cell viability in A2780 and A2780 
cisplatin-resistant cells. Treatment with the small molecule indeed decreased cell viability 
of both cell lines (Chapter 6, Table 1 pg 62.). Again, the IC50 values for the cells were in 
the low µM range. Furthermore, the IC50 values for cisplatin in these lines were in the low 
µM range for A2780 cells while A2780 cisplatin-resistant cells were not sensitive to 20 µM 
cisplatin (data not shown). These studies illustrate the usefulness of 25-4 in the treatment 
of refractory disease.  As most women who are treated for ovarian cancer will also face 
recurrent disease,97 on-going experiments are testing the ability of 25-4 to resensitize 
A2780 cisplatin-resistant cells to treatment with cisplatin to further assess the small 
molecule’s usefulness in the treatment of refractory disease. 
To explore the mechanisms behind the decreased viability seen in ovarian cancer 
cells treated with 25-4 and to determine if the small molecule would sensitize cells to 
treatment with cisplatin, SKOV3 ovarian cancer cells were treated with cisplatin, 25-4 or 
the combination and caspase 3/7 activity was monitored as activation of caspases is a 
hallmark of induction of apoptosis (Figure 6.5C pg 63).175 Treatment with 25-4 induced low 
levels of caspase 3/7 activation while induction of caspase activity was also low following 
treatment with cisplatin. When the two compounds were used in combination, marked 
induction of caspase 3/7 activity was observed, suggesting that 25-4 sensitizes SKOV3 
cells to treatment with cisplatin. In this study, doses of 25-4 and cisplatin than drive very 
little induction of caspase 3/7 activation (5 µM) at the given time point (24 h) were chosen 
for two reasons. We reasoned that combination with 2 very lose doses of drug will result 
in fewer off-target effects and would induce the least toxicity in vivo. Thus, selecting 
concentrations of drug that are not high enough to induce activation alone but give 
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induction together were chosen to reduce off-target effects and to reflect dosages we think 
would be most appropriate for in vivo use. 
No combination index was calculated for this study with SKOV3 cells because a 
dose-response curve for caspase 3/7 activation by 25-4 alone and cisplatin alone was not 
calculated, which would be required to calculate a combination index.147 In this 
experiment, caspase 3/7 activation by 24 hour treatment with 5 µM drug (25-4 alone, 
cisplatin alone or 5 µM of each drug) only was assessed. Future studies assessing 
caspase 3/7 activation by the compounds can be conducted in a dose-response format 
so these values can be measured to calculate combination index values. Again, the same 
methods mentioned for rescuing the phenotype of 25-4-treated cells in previous 
phenotypic screens could be used to establish that inhibition of IKKβ is the primary 
mechanism driving decreased cell proliferation and induction of caspase 3/7 activity. 
PARP is an enzyme that functions to repair DNA following cellular stress.176 The 
enzyme is the target of many proteases, including caspases, and its cleavage results in 
the production of PARP fragments that mediate diverse forms of cellular death.176 As 
inhibition of the NF-κB pathway induces apoptosis through inhibition of transcription of 
anti-apoptotic proteins21, 23-25 and PARP cleavage is a hallmark of induction of apoptosis,177 
we treated various cancer cell lines with 25-4 to see if the proposed IKKβ inhibitor could 
induce PARP cleavage in cancer cells (Figure 6.6 pg 64).  
MIAPaCa-2 and SKOV3 cells were treated with the indicated concentrations of 25-
4 and 25-18 and etoposide for 24 h. In 24 h, 25-4 induced PARP cleavage in MIAPaCa-2 
and SKOV3 cells and 25-18 was again inactive. Etoposide was used as a positive control 
in both of these experiments but does not show induction of PARP cleavage. MIAPaCa-2 
and SKOV3 cell lines were both particularly sensitive to induction of PARP cleavage upon 
treatment with 25-4. Thus optimizing the treatment concentration and length of 25-4 
exposure to induce PARP cleavage without inducing total cell death in these cell lines was 
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quite difficult. After performing initial dose-response experiments at the 48 hour time point 
(a time point when etoposide was expected to be active) and time-course experiments 
with multiple concentrations, the best concentration and drug exposure time for MIAPaCa-
2 and SKOV3 cells appeared to be 24 hour treatment with 10 µM 25-4. As such, I opted 
to treat MIAPaCa-2 and SKOV3 cells with etoposide for only 24 hours instead of treating 
with etoposide for 48 hours starting 1 day after cell plating and treating with 25-4 for 24 
hours starting 2 days after plating so an equivalent number of cells seeded on the same 
day would be treated with each drug. These experiments were carried out at the same 
time as those conducted with HeLa (48 hour treatment) and A2780 cells (96 hour 
treatment) and the same etoposide was used in these experiments and was indeed active 
48 and 96 hours following treatment. 
The range of treatment times required for induction of PARP cleavage in these cell 
lines is not surprising and has been noted with other small molecules. For example, 
staurosporine, a non-specific kinase inhibitor that inhibits IKKβ,178 has been shown to 
induce PARP cleavage in a matter of hours in some cells while induction of PARP 
cleavage takes at least a day in others.179 As such, the various time points required to 
induce PARP cleavage with 25-4 does not seem to be a phenomenon singular to these 
experiments. However, the lack of PARP cleavage by etoposide at the 24 hour time point 
in MIAPaCa-2 and SKOV3 cells is unlikely due to insensitivity to the drug. I suspect the 
lack of activity is due instead to the short time point for which cells were treated. As 
etoposide’s mechanism of action involves induction of DNA damage,180 at least one round 
of cell division would have needed to occur for etoposide to induce activation of PARP 
cleavage. Other small molecules that are known to inhibit signaling through the NF-κB 
pathway have to been shown to induce cleavage of caspases,181 which is required for their 
activation,182 within 4 hours of treatment. Such inhibitors or staurosporine may serve as 
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more appropriate controls in future experiments as they may induce their effects through 
the same pathway and at a relatively similar time point. 
Interestingly, a decrease in total PARP but no cleaved PARP fragment was seen 
in MIAPaCa-2, SKOV3 and A2780 cells treated with 25-4. This is again likely due again 
to the difficulties associated with optimizing the concentration and length of 25-4 
treatment. Time course experiments analyzing the activation of caspase 3 and caspase 
7, which are known to cleave PARP,177 in these cells lines may yield a better idea of the 
time points and appropriate treatment concentrations so these experiments may be 
repeated to produce results more typical of a PARP cleavage assay (namely, presence of 
total PARP and production of a PARP cleavage fragment by 25-4 and a positive control 
that is known to induce DNA damage). 
The difficulties associated with obtaining ideal results for this experiment are likely 
due to the nature of the experiment. The positive and negative controls chosen for this 
experiment (etoposide and 25-18, respectively) were indeed proper controls for showing 
induction of PARP cleavage and no effect on PARP cleavage (Figure 6.6 pg 64, A2780 
and HeLa lines). However, due to the differential sensitivity of some cell lines to treatment 
with 25-4, some lines were not incubated with etoposide for a period of time sufficient to 
see induction of PARP cleavage by the small molecule (Figure 6.6 pg 64, MIAPaCa-2, 
SKOV3). Furthermore, treatment with 25-4 showed reduction of full-length PARP levels in 
all cell lines though a cleaved PARP fragment was not seen in all cell lines. This is likely 
due to the difficulty of selecting a treatment time at which the 89 kDa cleavage fragment 
is present in cells at a level detectable by immunoblotting. Future work may refine the 
timing issues associated with the studies by using a positive control that induces PARP 
cleavage as rapidly as 25-4. Furthermore, harvesting cells at different time points may 
yield 25-4-treated lysates with both full-length and the 89 kDa PARP fragment. 
Furthermore, other cleavage fragments of PARP are known to be generated by enzymes 
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other than caspases 3 and 7 including calpains and cathepsins, which can drive caspase-
independent apoptosis.176 In future experiments, immunoblotting for these fragments can 
be performed to further study the cell death induced in cell lines by 25-4 treatment. 
Animal-based studies: 13-197 
To assess the ability of 13-197 to decrease tumor growth in a mouse model of 
pancreatic cancer, MIAPaCa-2 cells were orthotopically implanted into the flanks of nude 
mice, the mice were given two weeks to heal and were treated for 30 days with either 
vehicle control or 13-197. At the end of this study, tumor weights and volumes were 
analyzed as was metastasis (as measured by number of tumor nodules in other organs) 
and proliferation (Figure 5.11 pg 53). Treatment resulted in a decrease in all of these 
parameters.128 Though treatment with the IKKβ inhibitor TPCA-1 is associated with 
toxicity, mouse studies with the small molecule have shown reduced proliferation of lung 
cancer cells (as measured by Ki-67 staining), decreased PCNA staining and slower tumor 
growth,74 all of which mirror our observations in 13-197-treated mice and provide further 
proof that the effects of 13-197 are through inhibition of IKKβ. Furthermore, several groups 
have reported decreased tumor formation following inhibition of NF-κB activity by deletion 
of p65183 or by overexpression of the IκB superrepressor (nonphosphorylable IκB),184 
suggesting again that the effects of 13-197 mirror inhibition of IKKβ. 
The novel result of this experiment was the lack of toxicity seen with 30-day 
administration of 13-197,128 as ML120B and TPCA-1, for example, have proven toxic in 
previous studies. The lack of toxicity of the small molecule is likely due to the transient 
activation of IKKβ that was seen after stimulation of HEK293 cells with TNF despite pre-
treatment with 13-197. These studies offer initial validation of the theory that partially 
targeting IKKβ is a viable strategy for treating disease without inducing severe toxicity.163 
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Future studies in our lab will be focused on purifying endogenous IKKβ from cells 
stimulated with TNF for various times. Kinase assays with 13-197, purified IKKβ and 
IκB will be performed to further validate that 13-197 selectively inhibits a phosphorylated 
form of IKKβ to yield the pattern of inhibition of IκB phosphorylation seen upon pre-
treatment with 13-197 and stimulation with TNF. This will provide further proof that 13-
197 escapes the toxicities associated with previously published IKKβ inhibitors by allowing 
early activation of IKKβ upon induction with TNF. 
Animal-based studies: 25-4 
To continue investigating the anticancer properties of 25-4, our collaborators at 
Josephine Ford Cancer Center (Henry Ford Hospital) tested the small molecule in an 
orthotopic model of ovarian cancer. Two studies were conducted. In the first, a small dose 
escalation study with 25-4 was performed. Nude mice were injected with 2 million A2780 
cells and after 3 days mice were divided into 25-4-treated, cisplatin-treated or untreated 
groups. The small molecule 25-4 was dosed at 1, 2.5 or 5 mg/kg 25-4 daily for 4 weeks 
while cisplatin was dosed at 2 or 4 mg/kg on days 5, 9, 14 and 21. This dosing regimen 
for 25-4 was chosen as it was expected to produce detectable levels of 25-4 in plasma 
and that for cisplatin was chosen to avoid toxicity in the mice. Mice were then sacrificed 
and tumor weights were analyzed (Figure 6.7 pg 65). Treatment with 1 mg/kg cisplatin 
resulted in ~15% reduction in tumor weights while treatment with 2.5 mg/kg resulted in 
~20% reduction of tumor weights and 5 mg/kg treatment resulted in ~45% reduction in 
tumor weights. However, toxicity (blocked bowels) was noted at the highest dosage of the 
drug. Treatment with 2 mg/kg cisplatin resulted in ~25% reduction of tumor weights and 
treatment with 4 mg/kg resulted in ~75% reduction in tumor weights. Toxicity (blocked 
bowels) was also noted at the highest concentration of cisplatin. As NF-κB pathway 
inhibition has been shown to sensitize cancer cells to cisplatin110 and 25-4 sensitized 
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ovarian cancer cells to treatment with the drug in cell-based studies conducted in the lab, 
a follow-up study to assess the ability of 25-4 to sensitize A2780 cells in mice to cisplatin 
was performed. Following the same outline of the studies presented above, mice were 
treated with 2.5 mg/kg 25-4 and 2 mg/kg cisplatin in combination as these concentrations 
did not induce overt toxicity in mice but did reduce tumor weights. Treatment with the two 
in combination resulted in nearly ~70% reduction of tumor weight compared to 
approximately 20% (25-4) and 25% (cisplatin) reduction of tumor weights alone. 
 Immunohistochemistry studies were performed on ovarian tissues extracted from 
the mice following treatment (Figure 6.8 pg 66). Levels of Mcl-1 were analyzed in these 
tissues. Again, Mcl-1 is a known target gene of NF-κB and its upregulation likely plays a 
role in chemoresistance.185, 186 In mice treated with 25-4, Mcl-1 staining was reduced by 
approximately 66%. Treatment with cisplatin again resulted in a decrease similar to that 
seen with treatment with 25-4. The combination had a similar effect. 
Resistance to cisplatin has been associated with increased phosphorylation of 
IκB and NF-κB activity in cisplatin-resistant A2780 cells and cisplatin treatment has been 
shown to be less effective at reducing IκB phosphorylation and NF-κB activity in cisplatin-
resistant cells.82 Furthermore, treatment of ovarian cancer cells, including A2780 cells, 
with cisplatin has even been shown to activate IκB degradation in cells.187 This activation 
of the NF-κB pathway is hypothesized to be a mechanism by which cisplatin resistance 
develops and the up-regulation of anti-apoptotic proteins by NF-κB is likely key for the 
development of this resistance.188 As such, we expected treatment of A2780 tumor-
bearing mice with cisplatin and 25-4 to lead to a synergistic decrease in tumor size as we 
hypothesized that treatment with 25-4 would counter any NF-κB pathway activation by 
cisplatin or rescue any lost NF-κB inhibitory activity of cisplatin in any A2780 cells that had 
developed resistance during the course of the study. As decreased levels of Mcl-1 (an 
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anti-apoptotic protein under transcriptional regulation of NF-κB) were seen in our cisplatin-
treated mice and these levels were comparable to those seen in 25-4 treated mice, we 
concluded that our cisplatin-treated mice did not develop resistance to cisplatin and thus 
we did not observe the synergism in 25-4 and cisplatin-treated mice we hypothesized we 
would see. Given the downregulation of Mcl-1, and not upregulation of Mcl-1, by cisplatin, 
there was little potential for synergistic decrease of the protein’s levels in this study. That 
is to say, for these two small molecules that each reduced Mcl-1 staining by 66% to have 
shown synergistic decrease in Mcl-1 levels at these dosages, more than 100% reduction 
in the levels of Mcl-1 would have been required. 
Future studies could focus on testing the combination of 25-4 and cisplatin in 
A2780 cisplatin-resistant cells, which in our hands have shown 25-4 sensitivity similar to 
A2780 cells (IC50 = ~3 µM for A2780 cisplatin-resistant cells and ~2.3 µM for A2780 cells) 
but are insensitive to cisplatin at 5X the drug’s IC50 for A2780 cells (A2780 cisplatin-
resistant cells are insensitive at 20 µM while A2780 cells have an IC50 of ~4 µM) (data not 
shown). However, the cisplatin-resistant cells used in our studies do not form tumors in 
mice and were thus unable to be tested in the mouse model outlined above. Furthermore, 
a study in which mice with A2780 tumors are treated with low doses of cisplatin to induce 
resistance and then treated with 25-4 in combination with cisplatin to test if 25-4 treatment 
can resensitize ovarian cancer cells to cisplatin could be designed. It would be interesting 
to see if cisplatin-resistant A2780 tumors display increased levels of phosphorylated IκB, 
nuclear p65 and Mcl-1 during the development of resistance, suggesting that NF-κB 
activation does indeed drive chemoresistance. 
The novelty of these studies was again the lack of toxicity noted with a therapeutic 
dose of 25-4 (2.5 mg/kg). Previous studies testing the inhibition of the NF-κB pathway in 
ovarian cancer have shown decreased tumor weights in mice.189 Furthermore, NF-κB 
pathway inhibition by curcumin, an IKKβ inhibitor, has been shown to induce apoptosis in 
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ovarian cancer cells,190 which could be driven by reduced levels of the anti-apoptotic 
protein Mcl-1,185, 186 thus the activity of 25-4 in these models is aligned with the known 
consequences of inhibiting the NF-κB pathway in ovarian cancer cells. Again, treatment 
with cisplatin is known to induce NF-κB pathway activation in A2780 cells so the 
downregulation of Mcl-1 in cisplatin-treated cells and consequent lack of sensitization to 
cisplatin by 25-4 was unexpected. 
To ensure that the effects of 25-4 in this study were due to the inhibition of the NF-
κB pathway through inhibition of IKKβ and p65, two of its known targets, these studies 
could be expanded. More slides can be generated from our tumor microarray and 
analyzed for additional tumor properties that are known to be regulated by the NF-κB 
pathway such as proliferation (staining of Ki-67 or PCNA) and angiogenesis (CD31 
staining).190 Furthermore, as the NF-κB pathway is known to regulate the expression of 
cyclins,191 staining for cyclins could be performed. Importantly, tissue staining of 
phosphorylated and total IKKβ, IκB and p65 could be done to ensure the IKKβ was 
activated (high phospho-IKKβ staining) but inhibited (low phospho-IκB, phospho-p65 
staining) in tumor tissues. 
Upon sacrifice, gastrointestinal complications (likely constipation or impaction) 
were noted in mice treated with the highest dosages of 25-4 and cisplatin. Constipation is 
the slow movement of feces through the large intestine, while impaction is the build up of 
hardened feces in the colon. Constipation is commonly caused by the intake of too little 
water while impaction may also be associated with both cardiac and respiratory 
symptoms.192 Unfortunately, the mice in the study were not being monitored for water 
intake or cardiac or respiratory symptoms and these symptoms were not obvious to 
researchers conducting the study, so it is difficult to determine the specific reason for the 
observed blockages. These gastrointestinal complications, however, are among the most 
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common side-effects of treatment with chemotherapeutics192 and can usually be alleviated 
if brought to the attention of a physician. 
Lack of toxicity: 13-197 
Our HEK293 cell-based studies that suggest 13-197 targets a later-acting, 
phosphorylated form of IKKβ while allowing early activation of IKKβ (Figure 5.5 pg 47) 
served as our first clue that the small molecule may not exhibit the toxicities associated 
with other inhibitors of the kinase. The most recently solved crystal structure of human 
IKKβ has given us further insight in the mechanism of action of 13-197, though future 
studies with the small molecule and protein will be required to validate these hypothesizes. 
Shenping Liu et al. obtained the crystal structure of a dimer of human IKKβ in 
complex with the ATP competitive inhibitor K252a. In this structure, one IKKβ protomer 
was phosphorylated while the other was not (Figure 3.2 pg 26). Analysis of the activation 
loop of phosphorylated and unphosphorylated IKKβ suggests that upon phosphorylation 
of the T loop serine residues, the activation loop of phosphorylated IKKβ moves by 
approximately 21Å and the conformational changes induced upon phosphorylation results 
in IKKβ protomers with distinct conformations. Though the ATP binding sites are nearly 
identical in either state, the conformational changes that occur upon phosphorylation could 
allow for the design of non-ATP competitive inhibitors of IKKβ that discriminate between 
active and inactive kinase. For example, phosphorylation of the IKKβ T loop serine 
residues creates a binding site for its substrate IκB. Binding to this site in the active 
kinase is hypothesized to inhibit only the activated form of the kinase.47 
As our studies suggested that 13-197 preferentially targets phosphorylated IKKβ 
over nonphosphorylated IKKβ, which have nearly identical ATP binding sites, we 
outsourced kinase assays to Reaction Biology Corp. to test if 13-197 is a non-ATP 
competitive inhibitor. If the small molecule is preferentially targeting activated IKKβ, it 
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should be binding somewhere besides the ATP binding site. The results from these assays 
indicate that 13-197 is indeed a non-ATP competitive inhibitor (data not shown).  
The substrate binding site is one of the main sites that undergoes a conformational 
change upon phosphorylation of the kinase. To test that 13-197 competes with substrate 
binding of phosphorylated IKKβ, a binding assay may be performed with active IKKβ, 13-
197 and IκB. Immunoprecipitation of activated IKKβ followed by immunoblotting for IκB 
could be performed (and vice versa) after incubating the two proteins in the presence of 
increasing concentations of 13-197. If 13-197 treatment decreases binding of IκB to 
IKKβ, reduced levels of IκB would be co-immunoprecipicated with IKKβ with increasing 
concentrations of 13-197. To perform these studies, phosphorylated and active IKKβ (or 
constitutively active S177/181E IKKβ) would be incubated with a nonhydrolyzable ATP as 
ATP binding is a prerequisite for substrate binding to enzyme193 followed by incubation 
with 13-197 and IκB and immunoprecipitation. The use of activated IKKβ and 
nonhydrolyzable ATP would allow binding of both 13-197 and IκB to the site of interest 
in active IKKβ. Crystalization of 13-197 in complex with active IKKβ would, however, best 
elucidate how the small molecule binds the kinase. 
Lack of toxicity: 25-4 
Studies with the natural product parthenolide, which features the same -
methylene--butyrolactone that is present in IKKβ, binds to C179 of IKKβ and C38 of 
p65.122, 130 Studies with IKKβ and p65 mutants have shown that conversion of C179 of 
IKKβ to alanine and conversion of C38 to serine in p65 results in loss of inhibition by the 
small molecule as alanine and serine residues cannot react with the Michael acceptor of 
the natural product.122, 130 Using these same IKKβ and NF-κB mutants, we could confirm 
that binding to the proteins is through these same residues. 
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The newly solved crystal structure of human IKKβ with a phosphorylated and 
unphosphorylated protomer also gives insight into 25-4’s mechanism of action. In 
phosphorylated IKKβ, C179 (which is the target of parthenolide and the presumed target 
of 25-4) is solvent exposed. However, in unphosphorylated IKKβ, the T loop residues 
seem to be in a conformation that would not facilitate binding of 25-4 to C179. 
Unfortunately, critical residues of the activation loop were missing in the crystal structure 
of unphosphorylated IKKβ, so how accurately this structure reflects the true structure of 
unphosphorylated IKKβ is highly debatable. Moving forward, we will conduct work that 
establishes a mechanism for the lack of toxicity of 25-4. Experiments similar to those 
conducted with 13-197 and TNF-stimulated cells will be performed. HEK293 cells will be 
pretreated with drug for 2 hours and then the cells will be stimulated with TNF for 
increasing periods of time. If pre-treatment with 25-4 results in the inhibition of IKKβ 
present at later time points after TNF stimulation, as was seen with 13-197, then 25-4 
could indeed preferentially inhibit phosphorylated IKKβ and the theories generated by 
review of this crystal structure could indeed be valid. Again, this experiment may need to 
be modified such that cells are stimulated first and then treated with drug as 25-4 also 
inhibits NF-κB function and may thus block the resynthesis of IκB and limit our abilities 
to assess IKKβ function as 25-4 treatment may affect our mechanistic readout (without 
IκB resynthesis we cannot monitor IκB phosphorylation at late time points) of its activity. 
Furthermore, 25-4 IC50 values for inhibition of IκB phosphorylation by inactive and 
activated IKKβ could be determined using IKKβ purified from cells at different time points 
(prior to and after stimulation of TNF) or S177/181A and S177/181E IKKβ (inactive, T 




Though these pre-treatment followed by stimulation with TNF studies can be 
readily conducted in our laboratory, identification of targets by mass spectrometry will give 
a much broader view into the off-target effects of the small molecule and a very focused 
answer to which form of IKKβ is targeted by 25-4. Briefly, streptavidin pulldowns of 
TAMRA-biotin-azide tagged 31-036-treated lysates will be performed to isolate proteins 
targeted by 31-036. These protein targets will be analyzed by mass spectrometry to 
determine binding partners of 31-036. Importantly, the structure of 25-4 is highly amenable 
to modification with functional groups that will allow us to perform subsequent SAR studies 
with 25-4 analogs. These studies will be aimed at identifying analogs that bind a single or 
a small subset of the targets of 25-4, so we may study the effects of targeting each protein 
that covalently interacts with the small molecule. 
Interestingly, despite targeting both IKKβ and p65, 25-4, like parthenolide, 
displayed little toxicity in mice. Even if the small molecule preferentially targets activated 
IKKβ, it must also target an activated form of p65 to prevent total shutdown of the pathway. 
It is possible that prior to its degradation, IκB’s interaction with p65 blocks 25-4 binding 
to p65, possibly through alteration of the protein’s structure. Though 25-4 is expected to 
bind to targets quickly (within 5 minutes), the time required for 25-4 to bind to p65 after 
the protein’s release from IκB may be just long enough to allow a pool of p65 to 
translocate to the nucleus and drive transcription necessary for survival of normal cells, 
particularly T and B cell precursors as their death is associated with the inhibition of the 
NF-κB pathway.162 However, this level of NF-κB transcription may not be sufficient for the 
survival of cancer cells, providing a therapeutic window for the small molecule. Again, 
partial inhibition of the pathway with small molecules is predicted to be less toxic than 




Click chemistry with 25-4 analog 31-036 
We chose to pursue click chemistry followed by reaction with an azide- or biotin-
azide-tagged TAMRA so we could perform visualization of targets via fluorescence and 
purification of targets via the high affinity interaction between biotin and streptavidin beads 
or resins, as these are emerging as very powerful techniques for the visualization and 
analysis of cellular targets of small molecules. Click chemistry reactions are particularly 
attractive for a number of reasons: 1) they are fast, high-yielding and relatively easy to 
optimize, 2) the azide and alkyne functional groups used in our reaction interact only with 
one another under the conditions of click chemistry and 3) click-based methods are 
compatible with the cellular environment allowing the reaction to occur in live cells. 
However, in designing a click probe, certain considerations must be taken. For example, 
the click probe must retain the binding properties of its parent small molecule (that is to 
say, 31-036 must display the same activity as 25-4). Furthermore, the click probe needs 
to retain cell permeability to be used in live cells.160 In the initial validation of 31-036 as a 
viable click probe, we incubated the probe with live cells at a concentration comparable to 
those used in studies with 25-4, washed away excess probe, harvested cells, performed 
the click reaction with TAMRA-azide and used in-gel fluorescence to ensure that the probe 
was indeed able to bind targets within live, intact cells (Figure 6.9 pg 67). We also 
performed dose- and time-response studies with the small molecule to investigate what 
concentration of the molecule was required to saturate our signal and how quickly the 
small molecule could bind targets (Figure 6.10 pg 68). These studies gave us an idea of 
the best concentration of the small molecule to use in follow-up studies and how short of 
an incubation we could perform with the small molecule. 
Furthermore, we performed a very rudimentary competition assay with 31-036 and 
25-4 (Figure 6.11 pg 69) based upon the methodologies of Kwok et al.122 to demonstrate 
that 25-4 and 31-036 bind similar targets in cells. In this experiment, cells were incubated 
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with 31-036 for 1 hour, 25-4 for 1 hour, or 25-4 for 1 hour followed by 31-036 for 1 hour. 
Cells were harvested, lysates were incubated with TAMRA-azide and resolved on SDS-
PAGE and in-gel fluorescence was visualized. These experiments show that when cells 
are pre-treated with 25-4 prior to treatment with 31-036, the intensity of the 31-036 click 
signature is diminished. This experiment is limited by the fact that I was unable to obtain 
a loading control. 
 Additional experiments to outline binding of 31-036 to the same targets of 25-4 will 
be conducted in the future. In these experiments, the same treatment strategy as above 
will be performed (treatment with 31-036 only, treatment with 25-4 only, and treatment 
with 25-4 followed by treatment with 31-036). However, a wide range of 25-4 
concentrations will be used. In these studies, concentrations of 25-4 that are equivalent to 
1/10X, 1X, and 10X 31-036 with intervening concentrations will be used to show dose-
responsiveness and complete loss of the 31-036 click signature. 
 The most recent click chemistry studies to have been conducted were reactions 
designed to ensure that TAMRA-azide and TAMRA-biotin-azide bind to the same targets 
in cells (Figure 6.13 pg 70). As the addition of a large group such as biotin may have 
affected the ability of the TAMRA-biotin-azide to access all the alkyne-tagged proteins (in 
their native state) available to TAMRA-azide,160 these initial studies were key for verifying 
that click reactions using TAMRA-biotin-azide would be similar to those with TAMRA-azide 
in native conditions. In these experiments, I verified that TAMRA-biotin-azide was indeed 
binding to the same targets in cells as assessed by a similar in-gel fluorescence click 
signature. Furthermore, I demonstrated that TAMRA-biotin-azide reacted with the alkyne 
tag of 31-036-bound p65. IKKβ was not used in this experiment due to difficulties 
associated with purchasing IKKβ in a buffer solution that does not contain compounds 
(glutathione and dithiothreitol) that will affect the reaction between 31-036 and the target 
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cysteine residue of IKKβ. Moving forward we will use this trifunctional TAMRA-biotin-azide 
to complete the mass spectrometry studies that have already been suggested. 
Determining the form of IKKβ targeted by 13-197 and 25-4 
We hypothesize that 13-197 and 25-4 inhibit IKKβ activity without inducing the 
toxicities associated with previously reported IKKβ inhibitors by specifically targeting 
activated IKKβ without binding resting, inactivated IKKβ. In this model (Figure 3.6 pg 32) 
IKKβ would be briefly activated by TNF, allowing short activation of IKKβ prior to small 
molecule binding. We hypothesize that this brief activation provides enough signaling 
through the NF-κB pathway to allow proper immune functioning (data not shown). 
However, the inhibition of activated IKKβ by these small molecules would inhibit sustained 
activation of IKKβ. This selective inhibition of activated IKKβ appears to be sufficient to 
drive death or reduce viability of cancer cells (Figure 5.9, 5.10, 5.11, 6.4, 6.5, 6.6, 6.7 on 
pgs 50, 51, 53, 62, 63, 64, and 65, respectively and Table 1 pg 62).  
To verify that 13-197 indeed inhibits a phosphorylated form of IKKβ, I have recently 
identified IKKβ antibodies that can be used to immunoblot and immunoprecipitate 
unphosphorylated and phosphorylated IKKβ. Using these antibodies, I will repeat the 
experiment shown in Figure 5.5 (pg 47) but will also immunoprecipitate IKKβ at various 
time points post-stimulation with TNF (0, 5, 10, 15, 30, 45, 50, 90 and 120 min post-
stimulation) and immunoblot lysate for both total and phosphorylated IKKβ and IκB. If 
phosphorylated IKKβ is present at the time points where inhibition of IκB phosphorylation 
by 13-197 is seen (90 and 120 min post-stimulation, for example) but little inhibition is 
seen at earlier time points, we may further assert that 13-197 indeed inhibits 
phosphorylated IKKβ. Furthermore, kinase and binding assays (see substrate binding 
experiments on pg 106) may be performed with immunoprecipitated phosphorylated IKKβ 
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to further demonstrate that 13-197 blocks phosphorylation of IκB by phosphorylated 
IKKβ. 
Analysis of the forms of IKKβ inhibited by 25-4 will be more straightforward. The 
above experiment described for 13-197 can be performed with 25-4 though treatment with 
the small molecule will occur following stimulation with TNF as 25-4 likely targets DNA 
binding by p65 and will block resynthesis of IκB, leaving no substrate for IKKβ at late 
time points. Additionally, click chemistry with 25-4 analog 31-036 will be performed with 
lysates collected at the same time points post TNF stimulation as described for 13-197. 
Pulldown with streptavidin beads will be performed following click chemistry with TAMRA-
biotin-azide and pulled down protein will be resolved by SDS-PAGE and transferred to a 
membrane. The membrane will be immunoprobed for total and phosphorylated IKKβ. If 
31-036 preferentially targets phosphorylated IKKβ, phosphorylated IKKβ will be pulled 
down in 31-036-treated lysates while nonphosphorylated IKKβ will not (will only see total 
IKKβ band in lanes with phosphorylated IKKβ). Again, endogenous IKKβ can be 
immunoprecipitated using anti-IKKβ antibody and kinase or IKKβ binding assays 
(visualized following click chemistry between 31-036 and TAMRA-azide) can be 
performed to demonstrate preferential inhibition of phosphorylated IKKβ by 25-4 and 31-
036. Furthermore, phosphorylated IKKβ can be confirmed as a target of 31-036 in the 
mass spectrometry studies previously proposed for identifying the targets of 25-4 analog 
31-036. 
Polypharmacology 
 Drugs commonly interact with multiple targets in cells and although these off-target 
interactions are generally associated with harmful side-effects, there is growing evidence 
that drugs that interact with multiple targets may still, and in reality do, provide therapeutic 
benefit. This emerging paradigm is termed polypharmacology and describes a drug that 
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targets 1) multiple members within a single signaling pathway or 2) multiple proteins that 
each play a role in a different signaling pathway, though these pathways may be 
interconnected. Examples of polypharmacological agents include aspirin, which covalently 
modifies at least 120 targets in cells and is used to treat a variety of indications.194, 195 
Furthermore, the anticancer medications sunitinib, pazopanib, sorafinib and dasatinib are 
known to inhibit multiple proteins. Not only do these drugs target multiple pathways and 
thus multiple processes known to drive cancer, but they also prevent drug resistance as 
they will still exert activity through their remaining targets even if one becomes resistant 
to treatment.194, 196  
With this in mind, though both 13-197 and 25-4 are known to target multiple 
proteins, we are confident future work to identify additional binding targets of 13-197 and 
25-4 and subsequent optimization of these small molecules using structure-based drug 
design will reduce undesirable, off-target effects by these drugs. Furthermore, the ability 
of these small molecules to target two proteins upstream of NF-κB-driven transcription 
(IKKβ and MAP4K4 in the case of 13-197 and IKKβ and p65 in the case of 25-4) as well 
as other targets possibly relevant to cancer (Nek3 for 13-197 and unknown targets of 25-
4) may be quite beneficial for overall activity in cells. Again, future studies with the 
compounds and their analogs will be required to test this. 
Rational design of IKKβ inhibitors 
In spite of the massive effort made by pharmaceutical companies to develop viable 
inhibitors of IKKβ, no such inhibitor has been approved for clinical use for the treatment of 
cancer. Nevertheless, cell- and animal-based studies continue to demonstrate the 
anticancer effects of IKKβ inhibition. The work outlined in this dissertation supports the 
hypothesis that IKKβ is indeed a viable target for anticancer research. By biasing our 
studies around a small molecule that allows the transient activation of IKKβ (13-197) and 
a targeting motif (-methylene--butyrolactone) of a natural product that inhibits IKKβ 
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without inducing severe toxicities, we were able to develop two small molecules that are 
active against IKKβ in cancer cell lines. Furthermore, these small molecules have shown 
promise in studies with clinically-approved therapeutics, again suggesting that IKKβ is a 
desirable target for anticancer research. Most importantly, these small molecules reduced 
tumor burden in mice without inducing toxicities, especially those associated with 
previously described IKKβ inhibitors. Future studies in our lab will outline the mechanistic 
basis for the non-toxic inhibition of IKKβ by these small molecules.  
As new information regarding the structure of resting and phosphorylated IKKβ are 
made available, structure-guided drug discovery efforts focused on IKKβ will likely lead to 
the development of next-generation IKKβ inhibitors. These new small molecules, along 
with the previously discovered IKKβ inhibitors, will allow drug discovery groups to perturb 
and study the poorly-understood regulation of IKKβ’s activity by its complex members and 
positive and negative regulators. These studies will provide valuable insights that will allow 
researchers to develop targeted IKKβ inhibitors that inhibit diseased states of the kinase 
that persist in cancer and other diseases without affecting the transient activation of IKKβ 
that appears to be necessary for normal cellular functioning. Rational design of IKKβ 
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